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1. INTRODUCTION 
Diabetes mellitus commonly referred as a Diabetes, it is a group of metabolic 
diseases in which there is high blood sugar levels over a prolonged period.1 Symptoms 
of high blood sugar include frequent urination, increased thrist, and increased hunger. If 
left untreated, diabetes can cause many complications.2 Acute complications can 
include diabetic ketoacidosis, non ketotic hyperosmolar coma, or death.3 Serious long 
term complications include heart disease, stroke, chronic kidney failure, foot ulcers, and 
damage to eyes.2 
 Diabetes is due to either the pancreas not producing enough insulin or the cells 
of the body not responding properly to the insulin produced.4 There are four types of 
diabetes mellitus: 
 Type 1 diabetes results from the pancreas‘s failure to produce enough insulin. 
This form referred as “insulin dependent diabetes mellitus” (IDDM) or “juvenile 
diabetes”. The cause is unknown.2 
 Type 2 diabetes begins with insulin resistance, a condition in which cells fail to 
respond to insulin properly. As the disease progress a lack of insulin may also 
develop. This form referred as “non insulin dependent diabetes mellitus” 
(NIDDM) or “adult onset diabetes”. The primary cause is excessive body weight 
and not enough exercise.2 
 Gestational diabetes is the third main form and occurs when pregnant women 
without a previous history of diabetes develop high blood sugar levels. They 
prone to diabetes in future.5 
 MODY Maturity Onset Diabetes of the Young is the fourth type of diabetes. 
Specific monogenetic defects of the beta-cells have been identified and usually 
give rise to maturity onset diabetes of the young (MODY). MODY is defined as a 
genetic defect in beta-cell function.6 
 Prevention and treatment involve maintaining a healthy diet, regular physical 
exercise, a normal body weight, and avoiding use of tobacco. Control of blood pressure 
and maintaining proper foot care are important for people with the disease. Type 1 DM 
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must be managed with insulin injections. Type 2 DM may be treated with medications 
with or without insulin.7 Insulin and some oral medications can cause low blood sugar.8 
Weight loss surgery in those with obesity is sometimes an effective measure in those 
with type 2 DM.9 gestational diabetes usually resolves after the birth of the baby. Mody 
type diabetes managed by sufonylureas treatment.6 
 As of 2015, an estimated 415 million people had diabetes worldwide, with type 2 
DM making up about 90% of the cases. This represents 8.3% of the adult population, 
with equal rates in women and men. As of 2014, trends suggested the rate would 
continue to rise. Diabetes at least doubles a person’s risk of early death. From 2012 to 
2015, approximately 1.5 to 5.0 million deaths each year resulted from diabetes.10  
ROLE OF PHYTOMEDICINE IN THE TREATMENT OF DIABETES
 
The Ayurvedic concept appeared and developed between 200 and 500 B.C. in 
India. The literal meaning of ayurveda is “science of life”, because ancient Indian 
system of health care focused views of man and his illness. It is pointed out that the 
positive health means metabolically well- balanced human beings. Ayurveda remains an 
important system of medicine and drug therapy in India.10  
In Ayurveda, diabetes falls under the term madhumeha. Various types of herbal 
preparations such as decoctions (boiled extracts), swaras (expressed juices) Asav-
Arishta (fermented juices) and powders have been mentioned for the treatment of 
madhumeha. These indigenous medicines may not have adverse effects in therapeutic 
doses. It is mentioned in ancient texts such as the Charkas Samhinta that a single herb 
exerts different actions on many diseases and that each herb may have one dominating 
effect and other comparatively subsidiary effects. It is also mentioned that an herbal 
drug can also have synergistic and antagonistic effects in combination with other 
herbs.11  
Out of an estimated 250000 higher plants, less than 1% have been screened 
pharmacologically and very few in regard to diabetes mellitus.13 In India, indigenous 
remedies have been used in the treatment of DM since the time of Charaka and 
Sushruta (6th century BC). Plants have always been an exemplary source of drugs and 
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a many of the currently available drugs have been delivery directly or indirectly from 
them. Ethnopharmacological surveys indicate that more than 1200 plants are used in 
traditional medicine for their alleged hypoglycaemic activity. Medicinal plants, since 
times immemorial, have been used in virtually all cultures as a source of medicine.14 
The natural detoxification process of the body is effectively enhanced by herbal 
medicines and also very good in boosting the immune system and also herbal 
medicines in the treatment of a disease take into account pathogens, whole body 
balance, body chemistry with scientific proof of them in the treatment of a disease. 
Because of all these reasons, herbal medicines are preferred. Wide array of plant 
derived active principles have demonstrated their anti-diabetic activity. The main active 
constituents of these plants include guanidine, steroids, carbohydrates, glycopeptides, 
terpenoids, glycosides, flavanoids, alkaloids, amino acids and inorganic ions. These 
affect various metabolic cascades, which directly or indirectly affect the level of glucose 
in the human body.15 
PHYTOCONSTITUENTS HAVING ANTI DIABETIC ACTIVITY 
16,17 
The constituents that come under the category of polysaccharides, peptides, 
alkaloids, glycopeptides, triterpenoids, amino acids, steroids, xanthenes, flavanoids 
lipids, phenoics, coumarins, irirods, alkyl disulfides, inorganic ions and guanidine have 
been reported to have anti-diabetic activity. Specifically the following constituents are 
reported to have anti-diabetic  activity, amino acid like hypoglycine A and hypoglycine B, 
alkaloids like catharanthine, leurosine, lochnerine, arecoline and vindoline, pinitol, 
epicatichin, bengalenoside, anemarans (A, B, C,D), atarctans (A,B,C), dioscorin 
(A,B,C,D,E,F), ephedrans (A,B,C,D,E), glycoprotein (moran A), mucilage, nimbidin, 
peptides (P insulin), S- methyl cysteine sulphoxide, S- allyl cysteine sulphoxide, 
andrographollide, allicin (thio-2- propene-1- sulfinic acid S-allyl ester), shamimin, beta 
vulgarosides I-IV, glycoside of leucopelargonidin and leucodelphindin, magniferin, 
marsupsin, pterosupin, pterostilbene, pinoline, naringin, salacinol, hesperidin, berberine, 
chlorgenic acid, charantin,  swerchirin, epigallocatechin gallate, trigonelline, harmane, 
norharmane, lactucaside, beta-sitosterol, lactucain C, kalopanax saponin A, gymnemic 
acid IV, hederagenin, furfuran lignin, oleanoloc acid, elatosides (E,G,H,I), cryptolepine, 
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caffeoyl glucoside, momordin Ic, bellidifolin, kolaviron, scoparianosides A, B and C, 
kaempferol glucosides,  bakuchiol, trihydroxyoctadecadienoic acids, escins (Ia,Ia,IIa,IIb 
and IIIa), thysanolactone, kotalanol, fagomine, 3-O-beta-D- glucopyranosylfagomine, 4-
O_beta- d glucopyranosylfagomine, 3-epifagomine. 
Myrciacitrins I and II, myrciaphenones A and B, momordin, prunin, tormentic 
acid, 8- debenzylpaenoniflorin, coutareagin, senticoside, lithosperman, senegin II, Z- 
senegasaponins a and b  and E and Z-senegasapponins, E and Z- senegins ( II, III and 
IV), boussingoside, paenoflorin,  pachymaran, saciharan, coixan, oleanolic acid 
glycosides, ginsenoside, laminaran, masoprocol, senticoside A, abelmosan, ursolic 
acid, trichosan also exhibit anti-diabetic activity. 
Flavones C- glycoside, icarin, neomyrtillin, kakonein, acarbose, voglibose, ferulic 
acid, brazilin, hyperin, sappanchalone, anisodamine, multiflorine, 3-deoxy sappanone, 
protosappanin A also have anti-diabetic activity. 
Oral hypoglycaemic agents like sulphonylureas and biguanides are still the major 
players in the management of the disease, but there is growing interest in herbal 
remedies due to the side effects associated with the oral hypoglycemic agents. Herbal 
medicines have been highly esteemed source of medicine throughout the human 
history. They are widely used today indicating that herbs are a growing part of modern 
high-tech medicine. In recent times, there has been a revived interest within the plant 
remedies. In this review article an attempt has been made to focus on hypoglyceamic 
plants and may be useful to the health professionals, scientists and scholars working in 
the field of pharmacology & therapeutics to develop evidence based alternative 
medicine to cure different kinds of diabetes in man and animals.17 
In addition, a major effort was directed towards discovery of novel anti-diabetic 
agents. The interest in herbal drug research continues with an expectation that 
someday rather the other day, we would be able to bring a safer and more effective 
compound with all the desired parameters of a drug that could replace the synthetic 
medicines, which resulted in the discovery of several patented compounds, 
cryptolepine, maprouneacin, 3β, 30-dihydroxylupen-20 (29)-en-2-one, harunganin, 
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vismin, and quinines SP 18905. The most interesting discovery was nor 
dihydroguaiaretic acid which besides being active orally in db/db diabetic mice, also 
lowered cholesterol levels. This is considered as the unique quality of herbs, which was 
not observed in any synthetic medicine. 
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2. REVIEW OF LITERATURE 
2.1 HUMAN PANCREAS 
2.1.1 ANATOMY AND PHYSIOLOGY 
 The pancreas is a glandular organ in the digestive system and endocrine system 
of vertebrates. In humans, it is located in the abdominal cavity behind the stomach. It is 
an endocrine gland producing several important hormones, including insulin, glucagon, 
somatostatin, and pancreatic polypeptide which circulate in the blood. The pancreas is 
also a digestive organ, secreting pancreatic juice containing digestive enzymes that 
assist digestion and absorption of nutrients in the small intestine. These enzymes help 
to further break down the carbohydrates, proteins, and lipids in the chyme.18 
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The pancreas is an endocrine organ that lies in the upper left part of the 
abdomen. It is found behind the stomach, with the head of the pancreas surrounded by 
the duodenum. The pancreas is about 15 cm (6 in) long.19  
Anatomically, the pancreas is divided into a head, which rests within the 
concavity of the duodenum, a body lying behind the base of the stomach, and a tail, 
which ends abutting the spleen. The neck of the pancreas lies between the body and 
head, and lies anterior to the superior mesenteric artery and vein. The head of the 
pancreas surrounds these two vessels, and a small uncinate process emerges from the 
posterior part of the head, and extends posterior to the superior mesenteric vein, and 
terminates at the superior mesenteric artery.20 
The pancreas is a secretory structure with an internal hormonal role (endocrine) 
and an external digestive role (exocrine). It has two main ducts, the main pancreatic 
duct, and the accessory pancreatic duct. These drain enzymes through the ampulla of 
Vater into the duodenum.21. 
2.1.2 FUNCTION OF PANCREAS 
2.1.2.1 THE EXOCRINE PANCREAS 
 The exocrine pancreas consist of acini, which resemble bunches of grapes. Each 
acinus consists of a single layer of 40-50 pyramidal epithelial cells surrounding a lumen. 
The epithelial cells produce the secretion (pancreatic juice) containing enzymes, ions 
and water. The cells become wider during active section. The base of the acinar cells 
are strongly basophylic owing to the presence of endoplasmic reticulum, where there is 
a high concentration of RNA. This part of the cells therefore stains darker with 
haemotoxylin and eosin. The apex of teh cells is abundant with secretory granules 
containing the zymogen precursors of the pancreatic enzymes. The number of secretory 
granules increases after fasting, and decreases after a meal.22 
 The lumen of the acini into intercalated duct. Intercalated ducts converg to make 
larger interlobular ducts, which in turn converge to make interlobular ducts. Interlobular 
ducts are found in the connective tissue septa between lobules. Interlobular ducts join to 
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form either the pancreatic or the accessory duct, these ducts drain in to the duodenum. 
In some cases, the pancreatic duct unites with the bile duct, the bile and pancreatic 
juice enter the duodenum together.18 
 2.1.2.2 THE ENDOCRINE PANCREAS 
 In the endocrine pancreas, the islets of langerhans are embedded in the exocrine 
tissue. Each islet composed of 2-3 thousand epithelial cells. The epithelial cells are 
arranged in a compact structure that is pervaded by capillary network. A thin layer of 
reticular fibres separates the islets from the surrounding exocrine tissue. There are four 
different cell types within the islets of langerhans that each produce different hormones, 
they include: 
α cells- produce glucagon, typically located at the periphery of the islet. They are not 
present in all islets. 
β cells- produce insulin. The predominant cell type, located in the centre of islet and 
contributing to 70% of all cells. 
δcells- produce somatostatin. There are low numbers in all islets. 
F cells- produce pancreatic polypeptide and are few in number, they may be present in 
the exocrine tissues also (table no:1).23 
Table no 1: Pancreatic Islet Cells and Their Secretory Products23 
Cell Type 
Approximate Percent 
of Islet Mass 
Secretory Products 
A cell (α) 20 Glucagon,Proglucagon 
B cell (β) 75 Insulin,C-peptide, Proinsulin, Islet 
amyloid polypeptide (IAPP) 
D cell (δ) 3-5 Somatostatin 
F cell ( PP cell) <2 Pancreatic polypeptide (PP) 
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2.2 INSULIN 
Insulin  is a peptide hormone produced by beta cells of the pancreatic islets, and 
by the Brockmann body in some teleost fish.24 It has important effects on the 
metabolism of carbohydrates, fats and protein by promoting the absorption of, 
especially, glucose from the blood into fat, liver and skeletal muscle cells. In these 
tissues the absorbed glucose is converted into either glycogen or fats (triglycerides), or, 
in the case of the liver, into both.25 Glucose production (and excretion into the blood) by 
the liver is strongly inhibited by high concentrations of insulin in the blood. Circulating 
insulin also affects the synthesis of proteins in a wide variety of tissues. In high 
concentrations in the blood it is therefore an anabolic hormone, promoting the 
conversion of small molecules in the blood into large molecules inside the cells. Low 
insulin levels in the blood have the opposite effect by promoting widespread 
catabolism.26 
The pancreatic beta cells (β cells) are known to be sensitive to the glucose 
concentration in the blood. When the blood glucose levels are high they secrete insulin 
into the blood; when the levels are low they cease their secretion of this hormone into 
the general circulation. Their neighboring alpha cells, probably by taking their cues from 
the beta cells, secrete glucagon into the blood in the opposite manner: high secretion 
rates when the blood glucose concentrations are low, and low secretion rates when the 
glucose levels are high. High glucagon concentrations in the blood plasma powerfully 
stimulate the liver to release glucose into the blood by glycogenolysis and 
gluconeogenesis, thus having the opposite effect on the blood glucose level to that 
produced by high insulin concentrations. The secretion of insulin and glucagon into the 
blood in response to the blood glucose concentration is the primary mechanism 
responsible for keeping the glucose levels in the extracellular fluids within very narrow 
limits at rest, after meals, and during exercise and starvation.25,27  
When the pancreatic beta cells are destroyed by an autoimmune process, insulin 
can no longer be synthesized or be secreted into the blood. This results in type 1 
diabetes mellitus, which is characterized by very high blood sugar levels, and 
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generalized body wasting, which is fatal if not treated. This can only be corrected by 
injecting the hormone, either directly into the blood if the patient is very ill and confused 
or comatosed, or subcutaneously for routine maintenance therapy, which must be 
continued for the rest of the person’s life. The exact details of how much insulin needs 
to be injected, and when during the day, has to be adjusted according to the patient’s 
daily routine of meals and exercise, in order to mimic the physiological secretion of 
insulin as closely as is practically possible.28 
2.2.1 NORMAL INSULIN PHYSIOLOGY 
The insulin gene is expressed in the β- cells of the islets of langerhans, where 
insulin is synthesized and stored in the form granules before secretion. Release from 
beta cells occurs as a biphasic process involving two pools of insulin.30 
Like other peptide hormones, insulin is synthesized as a precursor 
(Preproinsulin) in the rough endoplasmic reticulum. Preproinsulin is transported to the 
Golgi apparatus, of uncertain function called C-peptide. Insulin and C-peptide are stored 
as granules in beta-cells, and are normally co-secreted by exocytosis in equimolar 
amounts together with smaller and variable amounts of proinsulin.29 
A rise in the blood glucose level calls forth an immediate release of insulin that is 
stored in the β-cells granules. If the secretory stimulus persists, a delayed and 
protracted response follows, which involves active synthesis of insulin.30 
The main factor controlling the synthesis and secretion of insulin is the blood 
glucose concentration. β-cells respond to both absolute glucose concentration and to 
the rate of change of blood glucose. Other stimuli to insulin release include amino acids 
(particularly arginine and leucine), fatty acids and the parasympathetic nervous system, 
peptide hormones of the gut and drugs that act on sulfonylurea receptors.29       
Insulin is the major anabolic hormone. It is necessary for 30 
(1) Trans membrane transport of glucose and amino acids 
(2) Glycogen formation in the liver and skeletal muscles 
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(3) Nucleic acid synthesis  
(4) Protein synthesis. 
(5) Conversion of glucose into triglycerides 
The principle metabolic function of insulin is to increase the rate of glucose transport 
into certain cells of the body which are striated muscle cells, including myocardial cells; 
fibroblasts and the fat cells, representing collectively about two third of the entire body 
weight.30 
Insulin interacts with its target cells by first binding to the insulin receptor; the 
number and function of these receptors are important in regulating the action of insulin. 
The insulin receptor is a tyrosine kinase that triggers a number of intracellular 
responses that effect metabolic pathways. One of the important early responses to 
insulin involves translocation of glucose transport units (GLUTs, of which there are 
many tissue- specific types) from the Golgi apparatus to the plasma membrane, which 
facilitates cellular uptake of glucose. Hence, removal of glucose from the circulation is a 
primary outcome of insulin action.30 
2.2.2 BIPHASIC INSULIN RESPONSE TO A CONSTANT GLUCOSE STIMULUS31 
      When the β- cells are stimulated, there will be a rapid first phase insulin response 1-
3 minutes after the glucose level is increased; this returns towards baseline in 6-10 
minutes later. Thereafter, a gradual second phase insulin response that persists for the 
duration of the stimulus. Type 2 diabetes mellitus is characterised by loss of the first 
phase insulin response and a diminished second phase response. 
2.2.3 EFFECT OF INSULIN ON ITS TARGETS23 
                    Insulin promotes the storage of fat as well as glucose (both are sources of 
energy) within specialised target cells. (Fig no.2) Insulin promotes synthesis (from 
circulating nutrients) and storage of glycogen, triglycerides and protein in its major 
target tissues: liver, fat and muscle. The release of insulin from the pancreas is 
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stimulated by increased blood glucose, vagal nerve stimulation and other factors (fig 
no.2). 
 
Fig. no- 2: Effect of Insulin on its targets 
 
2.2.4 ENDOCRINE EFFECTS OF INSULIN 23 
EFFECTS ON LIVER 
 Reversal of catabolic features of insulin deficiency. 
 Inhibits glycogenolysis. 
 Inhibits the conversion of fatty acids and amino acids into keto acids. 
 Inhibits conversion of amino acids to glucose 
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  Produces anabolic action  
 Promotes glucose storage as glycogen (induces glucokinase and                          
glycogen synthase and inhibits phosphorylase). 
 Increases triglycerides synthesis and very low density lipoprotein 
formation. 
EFFECT ON MUSCLE 
 Increases protein synthesis 
 Increases amino acid transport. 
 Increases ribosomal protein synthesis. 
 Increases glycogen synthesis. 
 Increases glucose transport. 
 Induces glycogen synthesis and inhibits phosphorylase. 
EFFECT ON ADIPOSE TISSUE  
 Increases triglyceride storage. 
 Lipoprotein lipase is induced and activated by insulin to hydrolyse 
triglycerides from lipoproteins. 
 Glucose transport into cells provides glycerol phosphate to permit 
esterification of fatty acids supplied by lipoprotein transport. 
 Intracellular lipase is inhibited by insulin. 
2.2.5 INSULIN AND CARBOHYDRATE METABOLISM32 
After eating, various foods are broken into sugars in the stomach. The main 
sugar is glucose which passes through the blood stream. But to remain healthy, the 
blood glucose levels should not go too high or too low. 
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When the blood glucose level starts to rise (after having food), at the same time 
the level of the hormone called insulin also rises. 
Insulin is the hormone that works on the body cells and helps them to take the 
glucose from the blood stream for producing energy and some is converted into stores 
of energy (glycogen or fat). 
When the blood glucose level begins to fall (between meals), at the same time 
the level of insulin also falls. When this happens the glycogen or fat is converted back 
into glucose which is released from the cells into the blood stream. 
2.2.6 INSULIN AND PROTEIN METABOLISM33 
The present status of protein synthesis within cells has been outlined. Protein is formed 
in the absence of insulin; the net formation of protein is accelerated by insulin. The 
effects of insulin on protein metabolism take place independently of the transport of 
glucose or amino acids into the cell; of glycogen synthesis; and of the stimulation of 
high energy phosphate formation. In the case of protein metabolism, as in certain 
studies on the pathways of glucose and fat metabolism, these observations reveal 
striking intracellular effects of insulin in many tissues. Within most tissues the effect of 
insulin appears to find expression predominantly at the microsomal level. Incidentally, 
other hormones which affect protein metabolism such as growth or sex hormones 
appear to act at the microsomes. The fact that insulin exerts effects on protein 
metabolism at other intracellular sites as well as the above independent effects leads 
one to agree that its action consists of a stimulation of multiple, seemingly unrelated, 
metabolic events. 
The fact that an immediate effect of insulin on protein synthesis is independent of the 
immediate need for extracellular glucose or amino acids does not mean that the 
sustained functioning of cells is likewise independent. The biochemist is fully aware of 
metabolic defects in diabetes which are not altered by insulin in vitro, but which demand 
varying periods of pre-treatment of the animal. It is also known that in diabetes some 
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proteins (enzymes) may be deficient while others may be prodced in excess in the 
absence of insulin. 
2.2.7 INSULIN AND FAT METABOLISM34 
The triacylglyceroles that comprise the bulk of lipids in the diet are hydrolyzed to free 
fatty acids, monoacylglyceroles and glycerol in the intestinal tract. During absorption 
through the intestinal tract mucosa, triacylglyceroles are re-synthesized from free fatty 
acids, and glycerol-3-phosphate is formed in the intestinal mucose. These globules, 
called chylomicrons, pass through the liver and adipose tissue, they are reduced in size 
by an enzyme, lipoprotein lipase (LPL). In the postabsorptive period, free fatty acids and 
glycerol are released from adipocytes by neural and hormonal stimulation. The free fatty 
acids can be burned by almost all tissues of the body except the brain. They are burned 
in the mitochondria by a process of b-oxidation to acetyl-CoA, which can then enter the 
citrate acid cycle for conversion to CO2, adenosine triphosphate, and water. When 
excessive quantities of glucose are ingested, the glucose can be converted to a storage 
form, triacylglycerol. Fatty acids are synthesized by a series of reactions in which acetyl-
CoA and malonylo-CoA residues sequentially condense until the fatty acid chain is 
completed. The fatty acids are then combined with glycerol-3-phosphate, generated in 
the liver, to form the neutral triacylglyceroles. The insulin has effects on both the 
synthetic (estrification) and breakdown (lipolysis) pathways. The promotion of 
triacylglycerol storage in fat is one of the most important of the actions of insulin 
DISORDERS OF PANCREAS35 
  Pancreatitis 
  Diabetes mellitus 
  Exocrine pancreatic insufficiency 
  Cystic fibrosis 
  Pseudocysts 
  Cysts 
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2.3 DIABETES MELLITUS 
Diabetes mellitus is simply referred to as diabetes which is either because the 
body does not produce enough insulin or because the cells do not respond to insulin 
that is produced. The classical symptoms of the diabetes mellitus are polyuria (frequent 
urination), polydipsia (increased thirst) and polyphagia (increased hunger). 
 
2.3.1 CLASSIFICATION OF DIABETES31 
The American diabetes association has proposed four types of diabetes based on their 
aetiology. They are; 
 Type 1 diabetes mellitus or insulin dependent diabetes mellitus (IDDM) 
 Type 2 diabetes mellitus or non insulin dependent diabetes mellitus (NIDDM) 
 Maturity onset diabetes of the young (MODY) 
 Gestational diabetes 
2.3.2 TYPE 1 DIABETES MELLITUS31 
               Type 1diabetes (previously insulin dependent diabetes mellitus (IDDM)) is 
characterised by beta –cell destruction, usually leading to absolute insulin deficiency 
and associated with usually juvenile onset, a tendency to ketosis and diabetic 
ketoacidosis and an absolute need for insulin treatment. Most patients have type1A 
diabetes, which is caused by a cellular mediated autoimmune destruction of the beta-
cells of the pancreas. 
2.3.3 PATHOGENESIS OF TYPE 1 DIABETES MELLITUS31   
             Type 1 diabetes mellitus (DM) is a disease of multi factorial autoimmune 
causation. Worldwide, there is a marked geographic variation in prevalence. The overall 
lifetime risk in Caucasian subjects is approximately 0-4%. Type 1 DM is caused by an 
interaction between environmental factors and an inherited genetic predeposition. 
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              In twin studies, a significant genetic contribution is suggested by a 
concordance value for type 1 DM of 30-50%. The risk to a first degree relative is 
approximately 5%. The high discordance rate supports the notion that type 1 DM is 
multifactorial in aetiology. Environmental triggers may account for up to two thirds of the 
disease susceptibility. About 20 different regions of the human genome have been 
found to have some degree of linkage with type 1 DM. To date, the strongest linkage 
has been with genes encoded in the human leukocyte antigen (HLA) region located 
within the major histocompatability (MHC), the contribution of which to disease risk is 
now designated IDDM 1. This appears to be the most powerful determinant of genetic 
susceptibility to the disease, accounting for approximately 40% of familial inheritance. 
More than 90% of patients who develop type 1 DM have either DR3, DQ2 or DR4, DQ 
haplotypes, whereas fewer than 40% normal controls who have these haplotypes. DR3-
DR4 heterozygosis is highest in children who develop diabetes before the age of 5 
years (50%) and lowest in adults  presenting with type 1 diabetes (20-30%) compared 
with an overall US population prevalence of 2.4%. specific polymorphism of the DQBI 
gene encoding the beta- chain of class II DQ molecules predispose to diabetes in 
Caucasians but not in Japanese. In contrast, the HLS-DQ6 molecule protects against 
the disease. HLA antigens (class I and II) are cell- surface glycoprotein that play crucial 
role in presenting auto-antigen peptide fragments to T lymphocytes and thus initiating 
an immune response. Polymorphism in the genes encoding specific peptide chains of 
the HLA molecules may therefore modulate the ability of beta cells derived antigens to 
trigger an autoimmune response against the beta- cells. 
                  Only one non- HLA gene has been identified with certainty and that is the 
insulin gene (INS) region on chromosomes 11p5.5, now designated as IDDm2. 
Population studies of Caucasian type 1 subjects and non- diabetic controls initially 
showed a positive association between alleles within the INS region and disease 
susceptibility. However, recent genome screens have provided conflicting data 
regarding the role of the INS gene region (IDDM2). It is thought that INS and HLA act 
independently in the causation of type-1 diabetes and that the INS gene region (IDDM2) 
accounts for 10% of familial clustering. 
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              The most likely environmental factor implicated in the causation of type-1 DM is 
viral infection. Numerous viruses attack the pancreatic beta – cell either directly through 
a cytolytic effect or by triggering an autoimmune attack against the beta cell. Evidence 
for a viral factor in aetiology has come from animal models and in humans, from 
observation of seasonal and geographic variations in the onset of disease. In addition, 
patients newly presenting with type 1 DM may exhibit serologic evidence of viral 
infection. Viruses that have been linked to human type 1 DM include mumps, Coxsackie 
B, retroviruses, rubella, cytomegalovirus and Epstein- Barr virus. Bovine serum albumin, 
a major constituent of cow’s milk has been implicated as a cause of type 1 DM in 
children exposed at an early age, but definite proof is lacking and this remains 
controversial. Nitrosamines (found in smoked and cured meats) may be diabetogenic as 
many chemicals known to be toxic to pancreatic beta- cells, including alloxan, 
sterptozotocin and the rat poison vector. Recent reports suggested that early ingestion 
of cereal or gluten increases the risk of type 1 diabetes and remain to be confirmed. 
           Type 1 DM is associated with autoimmune destruction of the bets cells of the 
endocrine pancreas. Examination of islet tissue obtained from pancreatic biopsy or that 
obtained from post-mortem patients with recent onset type 1 DM confirms a mono 
nuclear cell infiltrate (termed insulitis) with the presence of CD4 and CD8 T lymphocytes, 
B lymphocytes and macrophages suggesting that these cells have a role in the 
destruction of beta- cells. Although the precise mechanism of such as insulin has not 
been elucidated, it seems to be that an environmental factor, such as viral infection, in a 
subject with an inherited predisposition to the disease, triggers the damaging immune 
response. This results in aberrant expression of class II MHC antigen by pancreatic 
beta –cells. T lymphocytes recognise antigen presenting cells and are activated, 
producing cytokines such as interleukin (IL)-2, interferon (INF) and tumour necrosis 
factor (TNF). This generates a clone of T lymphocytes that carry receptors specific to 
the presented antigen. Such T-helper cells assist B lymphocytes to produce antibodies 
directed against the beta- cells. Such antibodies include islet cell antibodies (ICA) 
directed against cytoplasmic components of the islet cells. ICA presence may precede 
the development of type 1DM. Some subjects may develop ICA temporarily and not go 
on to develop the disease, but persistence of ICA leads to progressive beta- cell 
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destruction associated with the chronic inflammatory cell infiltrate termed ‘insulitis’. Type 
1 DM ensures. Other antibodies associated with type 1 DM are islet cell- surface 
antibodies (present in 30-60% of newly diagnosed type 1 DM patients), insulin 
antibodies (IAA0 and antibodies to an isoform of glutamic acid decarboxylase (GAD). 
 2.3.4 TYPE 2 DIABETES MELLITUS31 
                   Type 2 diabetes (previously non insulin dependent diabetes mellitus 
(NIDDM)) is associated with obesity and an onset later in life. Patients, at least initially 
and often throughout their lives, do not have a need for insulin therapy. The disorder 
manifests as a result of insulin resistance and relative insulin deficiency. A precise 
cause (or causes) has not been found. This type of diabetes frequently remains 
undiagnosed for many years despite affected individuals being at risk of developing 
serious macro vascular or micro vascular complications of the disease. Some patients 
may masquerade as type 2 diabetic patients, but ultimately are recognised as having a 
late onset slowly progressing immune mediated type 1 diabetes, so called latent 
autoimmune diabetes in adults (LADA). 
2.3.5 PATHOGENESIS OF TYPE 2 DIABETES MELLITUS31  
                     Subjects with type-2 DM exhibit abnormalities in glucose homeostasis 
owing to impaired insulin secretion, insulin resistance in muscle, liver, adipocytes and 
abnormalities of splanchnic glucose uptake. 
2.3.6 INSULIN SECRETION IN TYPE 2 DIABETES MELLITUS31 
                Impaired insulin secretion is a universal finding in patients with type 2 
diabetes. In the early stages of type 2 diabetes mellitus, insulin resistance can be 
compensated for by an increase in insulin secretion leading to normal glucose 
tolerance. With increasing insulin resistance, the fasting plasma glucose will rise, 
accompanied by an increase in fasting plasma insulin levels, until a fasting plasma 
glucose level is reached when the beta- cell is unable to maintain its elevated rate of 
insulin secretion at which point the fasting plasma insulin declines sharply. Hepatic 
glucose production will begin to rise. When fasting plasma glucose reaches high levels, 
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the plasma insulin response to a glucose challenge is markedly blunted. Although 
fasting insulin levels remain elevated, postprandial insulin and C-peptide secretory rates 
are decreased. This natural history of type 2 diabetes starting from normal glucose 
tolerance followed by insulin resistance, compensatory hyperinsulinemia and then by 
progression to impaired glucose tolerance and over diabetes has been documented in a 
variety of populations.  
Type 2 diabetes mellitus is characterised by loss of the first phase insulin 
response to an intravenous glucose load, although this abnormality may be acquired 
secondary to glucotoxicity. Loss of the first phase insulin response is important as this 
early quick insulin secretion primes insulin target tissues, especially the liver. There may 
be multiple possible causes of the impaired insulin secretion in type 2 diabetes mellitus 
with several abnormalities having been shown to disturb the delicate balance between 
islet neogenesis and apoptosis. Studies in first degree relatives of patients with type 2 
DM and in twins have provided strong evidence for the genetic basis of abnormal beta- 
cell function. Acquired defects in type 2 diabetes may lead to impairment of insulin 
secretion. Clinical studies in man and animal studies, have supported the concept of 
glucotoxicity, where by an elevation in plasma glucose levels, in the presence of a 
reduced beta- cell mass, can lead to major impairment in insulin secretion.  
Lipotoxicity has also been implicated as an acquired cause of impaired beta cell 
function. Patients with type 2 DM exhibit a reduced response of the incretin glucagon 
like peptide (GLP)-1 in response to oral glucose, while GLP-1 administration enhances 
the postprandial insulin secretory response and may restore near normal glycaemia. 
Amyloid deposits(islet amyloid polypeptide (IAPP) or amylin in the pancreas are 
frequently observed in patients with type 2 diabetes and have been implicated as a 
cause of progressive beta-cell failure. However, definitive evidence that amylin 
contributes to beta-cell dysfunction in humans is lacking. 
 
2.3.7 INSULIN RESISTANCE IN TYPE 2 DIABETES MELLITUS31 
             Insulin resistance is a characteristic feature of both lean obese individuals with 
type 2 diabetes. In the fasting state, plasma insulin levels are increased in patients with 
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type 2 diabetes. Since hyperinsulinemia is a potent inhibitor of hepatic glucose 
production, an excessive rate of hepatic glucose production is the major abnormality 
responsible for the elevated fasting plasma glucose in type 2 diabetes. It follows that 
there must be hepatic resistance to the action of insulin. The liver is also resistant to the 
inhibitory effect of hyperglycemia on hepatic glucose output. Most of the increase in 
hepatic glucose production can be accounted by an increase in hepatic 
gluconeogenesis. Muscle is the major site of insulin-stimulated glucose disposal in 
humans. Muscle represents the primary site of insulin resistance in type 2 diabetic 
subjects leading to a marketed blunting of glucose uptake into peripheral muscle. In 
contrast, splanchnic tissue like the brain is relatively insensitive to insulin with respect to 
stimulation of glucose uptake. Following glucose ingestion, both impaired suppression 
of hepatic glucose production and decreased muscle glucose uptake are responsible for 
the observed glucose intolerance leading to hyperglycemia. 
                 There is a dynamic relationship between insulin resistance and impaired 
insulin secretions. Insulin resistance is an early and characteristic feature of type 2 
diabetes in high risk populations. More over diabetes develops only when the beta –
cells are unable to increase sufficiently their insulin output compensate for the defect in 
insulin action (insulin resistance). Insulin resistance in type 2 diabetes is primarily due to 
post binding defects in insulin action. Diminished insulin binding is modest and 
secondary to down-regulation of the insulin receptor by chronic hyperglycemia. Post- 
binding defects that have been recognised include reduced insulin receptor tyrosine 
kinase activity, insulin signal transduction abnormalities, decreased glucose transport, 
diminished glucose phosphorylation and impaired glycogen synthatase activity. 
Quantitatively, impaired glycogen synthesis represents the major abnormality 
responsible for insulin resistance in type 2 diabetic patients. 
2.3.8 MATURITY ONSET DIABETS OF THE YOUNG (MODY)31 
                 Specific monogenetic defects of the beta-cells has been identified and 
usually gives rise to maturity onset diabetes of the young (MODY). MODY is defined as 
a genetic defect in beta-cell function. 
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 2.3.9 PATHOGENESIS OF MODY31 
           Maturity onset diabetes of the young (MODY) is inherited as an autosomal 
dominant and, upto date, abnormalities at six genetic locations on different 
chromosomes have been identified. The most common form of MODY is associated 
with mutations on chromosome 12 in hepatic nuclear factors (HNF)-1α and hence this is 
referred to as transcription factor MODY. Other mutations affect such transcription 
factor as HNF-1β, HNF-4α, insulin promoter factor-1 and NEUROD-1. Transcription 
factor mutations alter insulin secretion in the mature β-cells as well as altering β-cell 
development, proliferation and cell death. Cell dysfunction ensues until the emergence 
of frank diabetes. Patients with transcription- factor mutations tend to be lean and 
insulin sensitive rather than obese and insulin-resistant. Microvascular complications 
are frequent. The first gene implicated in MODY was the glucokinse gene. Mutations on 
the glucokinse gene on chromosome 7 result in a defective glucokinase molecule.  
Glucokinse converts glucose to glucose-6-phosphate, the metabolism of which 
stimulates insulin secretion by the β-cells tehreby glucokinase serves as a ‘glucose 
sensor’. With defects in the glucokinase gene, increased plasma levels of glucose are 
necessary to elicit normal levels of insulin secretion. Over 100 glucokinase gene 
mutations have been found in families from several different countries. Fasting 
hyperglycemia is present from both and worsens very slowly with age. Subjects are 
usually detected by screening, e.g. in pregnancy or during coincidental illness or by 
family studies. The mild hyperglycemia of this type of MODY rarely needs any treatment 
other than diet and microvascular complications are rare. 
         Other specific genetic defects leading to diabetes include point mutations in 
mitochondrial DNA, genetic abnormalities which leads to the inability to convert 
proinsulin to insulin and the production of mutant insulin molecules and also the 
mutations of the insulin receptor. Diabetes may also result from over disease of 
exocrine pancreas, secondary to endocrinopathies and also due to some drugs and 
chemicals. Viruses like cytomegalovirus, coxsackievirus B, adeno virus, mumps and 
congenital rubella are also associated in the destruction of β-cells. Genetic syndromes 
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like Down’s syndrome, Turner’s syndrome, Wolfram’s syndrome, Klinefelter’s syndrome 
are accompanied by an increased incidence of diabetes mellitus.   
 2.3.10 GESTATIONAL DIABETES MELLITUS31 
              Gestational diabetes mellitus (GDM) was first defined as decreased 
carbohydrate tolerance that develops or may be identified during pregnancy and this 
definition was changed in 2010 as that GDM is a carbohydrate intolerance that develops 
during pregnancy or has been discovered for the first time during pregnancy which is 
not diabetes. Therefore, the GDM definition was not included in overt diabetes in 
pregnancy. 
PATHOGENESIS31 
             Gestational diabetes mellitus (GDM) is a carbohydrate intolerance that 
develops first time during pregnancy. Type 1 and type2 diabetes also presents in 
pregnancy occasionally. For GDM there is lack of agreed diagnostic criteria, but this 
should not detract from the detrimental impact of maternal hyperglycemia on the 
pregnancy and the future health of the mother and the child. The American Diabetes 
Association recommends immediate recommendation for those women who are to be at 
high risk of GDM with marked obesity, previous history of GDM, glycosuria or strong 
family history of diabetes.  
           The fasting plasma glucose ≥126 mg/dl (7mmol/1) or a random plasma glucose 
≥200 mg/dl (11mmol/1) meets the threshold for diagnosis of GDM and should conform 
on a subsequent day. 
       In high-risk and average-risk women of GDM, it will not be found in the initial 
screening and they should be screened between 24 and 26 weeks of gestation by either 
a one-step approach using a 100g oral glucose tolerance test (OGTT) or a two-step 
approach which involves in measuring the plasma glucose level 1 hour after a 50g oral 
glucose load and performing a 100 g OGTT on those women who exceed the glucose 
threshold 1 hour after the 50g oral glucose load. 
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          As if the glucose threshold value is ≥140mg/dl (7.8 mg/dl), then around 80% the 
woman is with GDM. The diagnostic criteria for the 100 g OGTT are as follows; 
≥95mg/dl (5.3mmol/1) fasting and ≥180 mg/dl (10mmol/1) at 1 hour, ≥155 mg/dl 
(8.6mmol/1) at 2 hours and ≥140 mg/dl (7.8mmol/1) at 3 hours. To diagnose the GDM, 
two or more of the plasma glucose values must meet or exceed. In many countries 
these testing methods are not used and therefore a 75g IGTT was recommended by the 
WHO.  
          Gestational diabetes mellitus is mainly seen in women with obesity, increased 
maternal age and groups with a high background incidence of type 2 diabetes mellitus. 
GDM usually occurs after the middle of the second trimester and can be detected by 
suitable screening tests especially in the persons who are at high risk.  
          Prenatal morbidity in gestational diabetes mellitus increases with an increase in 
maternal hyperglycemia. Most of the pregnancy related morbidity of gestational 
diabetes mellitus is associated with delivering a large–fore gestational- age infant. 
Caesarean rates have been increased due to increase in gestational diabetes patients 
but this type of caesarean delivery can be reduced by intensive management of 
maternal hyperglycemia. In the majority of the mothers with gestational diabetes, it can 
be managed by diet alone by a dietician. Along with the mother,  sequential tests will be 
done from the foetus to estimate the foetal growth and abdominal circumferences and 
also to identify features of inappropriate foetal growth and inform the mother the need of 
maintaining blood glucose level intensively. 
        The American Diabetes Association recommends that if the dietary management 
does not maintain fasting plasma glucose level below 5.8 mg/dl (105mmol/1) and the 2 
hour post prandial glucose level below 6.7 mg/dl (120mmol/1), then insulin therapy 
should be considered. 
2.3.11 OTHER TYPES OF DIABETES MELLITUS31 
            Diabetes can also result from another process that adversely affects the 
pancreas and such acquired processes pancreatitis, trauma, pancreatectomy, 
pancreatic cancer. Hemochromatosis, fibrocalculous pancreatopathy and cystic fibrosis 
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may also cause diabetes. Diabetes may also caused by the other endocrine diseases 
especially when there is over-secretion of hormones that antagonize the normal effects 
of insulin including Cushing’s syndrome, acromegaly and pheochromocytoma. 
          Diabetes may also result from certain rare diseases associated with abnormalities 
of insulin or the insulin receptor which causes extreme insulin resistance and 
sometimes found in association with acanthosis nigricans. These disorders are 
categorized as insulin resistance syndromes. Diabetes may also occur due to a wide 
array of genetic syndromes like Down’s syndrome, Klinefelter’s syndrome, Turner’s 
syndrome. Diabetes may also result from the drugs like glucocorticoids, diazoxide, 
thiazides which have similar effect may also cause diabetes. 
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2.4 INSULIN DEFICIENCY31   
        Insulin deficiency results in increased hepatic glucose production and hence 
hyperglycemia by increased gluconeogenesis and glycogenolysis. Insulin deficiency 
also results in increased proteolysis releasing both glycogenic and ketogenic amino 
acids. Lipolysis is increased by elevating both glycerol and non-esterified fatty acid 
levels which further contribute to gluconeogenesis and keto genesis respectively which 
finally leads to hyperglycemia, breakdown of body fat and protein and academia. 
 
Fig no 3: The biochemical consequence of Insulin deficiency 
2.5 COMPLICATIONS OF DIABETES MELLITUS31 
        The morbidity associated with long standing diabetes of either types results in 
multiple complications mainly like macro vascular, microvascular and neurologic. The 
basis of these chronic long term complications is the great deal of research. The 
available experimental and clinical evidence suggests that most of the complications of 
the diabetes results mainly from the derangements by hyperglycemia. In addition, the 
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existence of hypertension is common in diabetes which leads to atherosclerosis. It is 
evident that when a kidney is transplanted to diabetic patient from non diabetic donors 
develops lesions due to diabetic nephropathy which is due to metabolic abnormalities in 
diabetic patients. Conversely, the kidneys with lesions due to diabetic nephropathy 
causes the reversal of the lesions when transplanted into the normal recipients 
2.5.1 MACROVASCULAR COMPLICATIONS36 
      Macro vascular refers to the large blood vessels of the heart, brain, and legs. The 
commonest manifestation of the macro vascular disease is in the coronary arteries and 
the legs. Atherosclerosis of the coronary arteries is common in most of the people with 
diabetes which is the most common cause for the death in people with diabetes which 
may occur at a much younger age than in the general population and even females are 
not immune in getting the disease. The mechanism for the development of macro 
vascular disease in people with diabetes is similar to that of people without diabetes 
which varies in the speed of development between diabetic and non-diabetic patients. 
The risk of coronary artery disease is enhanced at all levels by the risk factors like 
cholesterol, smoking, sedentary lifestyle, obesity, hypertension, etc 
2.5.2 MICROVASCULAR COMPLICATIONS36 
           A Microvascular disease affects capillaries all over the body and so the 
manifestations of the disease can be diffused. The eyes and kidneys are the most 
affected organs. In the eyes, retinopathy which causes blindness, cataracts and 
glaucoma are the complications. In kidneys, nephropathy accounts for half of the people 
who go for dialysis and receive kidney transplantation. 
2.5.3 PATHOGENESIS OF THE COMPLICATIONS OF DIABETES 
3 main mechanisms linking hyperglycemia to the complications of long-standing 
diabetes have been explored. Currently two such mechanisms are considered 
important. 
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 First mechanism30 
            Glucose chemically attaches to free amino acid groups of proteins without the 
aid of enzymes by the process called nonenzymatic glycosylation. The degree of this 
nonenzymatic glycosylation is directly related to the level of blood glucose. In the 
management of diabetes mellitus, the measurement of glycosylated haemoglobin 
(HbA1c) levels in blood is useful, because it provides an index of the average blood 
glucose levels over the 120 day life span of the erythrocytes. The early glycosylation 
products of collagen and other long lived proteins undergo a slow series of chemical 
rearrangements in the interstitial tissues and blood vessel walls to form irreversible 
advanced glycosylation end products (AGEs) and these products accumulate on the 
vessel wall over the life time. 
          AGE have a number of chemical and biological properties which are potentially 
pathogenic. 
           The formation of glycosylated end products (AGEs) on the proteins such as 
collagen causes cross-linkages between polypeptides, which may trap nonglycosylated 
plasma and interstitial proteins. The circulating low density lipoprotein (LDL) is trapped 
and retards its efflux from the vessel wall and promotes the deposition of cholesterol 
and thus causes atherogenesis. AGEs also affects the structure and function of 
capillaries including those on the glomeruli where the basement membranes become 
thickened and becomes leaky. 
           AGEs also bind to receptors of many cell types like monocytes, macrophages,  
endothelium and mesengial cells. The binding of AGEs on these receptors induces a 
variety of biological activities, which includes monocytes emigration, release of 
cytokines and growth factors from macrophages, increased endothelial permeability and 
enhanced proliferation of fibroblasts and smooth muscle cells and synthesis of 
extracellular matrix. All these effects can be potentially contributed to diabetic 
complications. 
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Second mechanism30 
          The second major mechanism proposed for the complications of intracellular 
hyperglycemia is the disturbances in the polyol pathways. Some tissues like nerves, 
lens, kidneys, and blood vessels do not require insulin for the transport of glucose, so 
hyperglycemia leads to an increase in intracellular glucose, which is then metabolised 
by aldose reductase into an polyol and eventually to fructose. Thus, the accumulated 
sorbitol and fructose leads to increase intracellular osmolarity and influx of water and 
then causes osmotic cell injury. In the lens, osmotically accumulated water causes 
swelling and opacity. The accumulation of sorbitol also impairs ion pumps and promotes 
the injury of Schwann cells and pericytes of retinal capillaries, with resultant peripheral 
neuropathy and retinal micro aneurysms. Inhibition of aldose reductase is capable of 
ameliorating the development of cataracts and neuropathy.   
 2.5.4 DIABETIC DYSLIPIDEMIA31 
                  Dyslipidemia is the major macro vascular risk factor for the macro vascular 
complications which leads to the cardiovascular diseases (CVD) in type 2 diabetes 
mellitus. Along with this, endothelial dysfunction, platelet hyperactivity, impaired 
fibrinolytic balance and abnormal blood flow which causes atherosclerosis and 
increases the risk of thrombotic vascular events. In type 2 diabetes mellitus, the most 
common lipoprotein abnormality is the elevation of triglycerides and very low density 
lipoprotein (VLDL) which is caused by the overproduction of VLDL triglycerides. 
The alteration in the distribution of lipids increases the risk of atherosclerosis in 
diabetic patients. So, the condition with insulin deficiency and insulin resistance was 
identified as phenotype of dyslipidemia in diabetes mellitus which is characterised with 
high plasma triglyceride level, low HDL cholesterol level and increased level of small 
dense LDL cholesterol. In addition to this, in diabetic patients, there will be an increment 
of free fatty- acid release which is due to insulin resistance. So, due presence of 
sufficient glycogen stores in the liver will promote triglyceride production which 
stimulates the secretion of apolipoprotein B (Apo B) and VLDL cholesterol. This 
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production of VLDL cholesterol by liver is enhanced due to the disability of insulin to 
inhibit the release of free fatty-acids. There are many associations between 
dyslipidemia and increased risk of cardiovascular disease in type2 diabetes mellitus 
patients due to increased triglyceride levels and low HDL cholesterol  
The management of dyslipidemia in diabetes mellitus includes changes in the 
lifestyle of the patients such as increased physical activity and dietary modifications. 
Besides this, antihyperlipidemic agents have been utilised for the management of 
dyslipidemia. For the prevention of primary and secondary cardiovascular disease in 
type 2 diabetes mellitus, anti platelet agents were recommended in contrast. 
Dyslipidemia is categorised as one of the cardiovascular risk factors beside to the family 
history of hypertension, CHD, smoking. Patients with type 2 diabetes mellitus having 
dyslipidemia are eligible for the prevention of cardiovascular disease with anti-platelet 
agents. 
2.6 SIGNS AND SYMPTOMS OF DIABETES MELLITUS37 
Polyuria (frequent urination) 
The insulin is ineffective, kidneys cannot filter the glucose back into the blood 
and the kidneys will take water from the blood to dilute the glucose which in turn fills up 
the bladder and causes frequent urination in diabetic patients. 
Polydipsia 
High thirst due to osmosis of water from cells into the blood in an attempt to 
dilute the high blood glucose concentration. 
Intense hunger 
Tendency to take food frequently more hunger and causes weight gaining. 
Unusual weight loss 
Weight loss is more common in patients with diabetes. As the body is not making 
enough insulin then the body will seek out for the other energy source where the cells 
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are not getting glucose. Muscle tissues and fat will be broken down for the energy to the 
cells. So, when these muscle tissues and fat is broken down automatically there will be 
loss in body weight. 
Blurred vision 
This can be caused by tissue being pulled from the eye lenses and effects the 
eye’s ability to focus and can be treated. If it is severe prolonged vision problems and 
blindness can occur. 
Other symptoms 
Cuts, bruises, skin or yeast infections do not heal properly or quickly because if 
there is more sugar in the body, its ability to recover from infections is affected. 
 Specially, it is difficult to cure bladder and vaginal infections in women with 
diabetes. 
Red and swollen gums 
If the gums are red, tender and swollen this could be the sign of diabetes. The 
gums will pull away the teeth and the teeth will become loose. Numbness / tingling in 
feet and palm 
2.6.1 Long-term complications of Diabetes:38,39 
 Microangiopathy: Ischemic heart disease (IHD), stroke, peripheral vascular 
disease. 
 Microangiopathy: retinopathy, nephropathy. 
 Neuropathy: peripheral neuropathy, autonomic neuropathy 
 Cataract 
 Diabetic foot 
 Diabetic heart                                                                                
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2.6.2 RISK FACTORS OF TYPE 1 DIABETES40  
 Family history 
 Genetics 
 Age 
 Exposure to certain virus, such as the Epstein-Barr virus, Coxsackie virus, 
mumps virus and cytomegalovirus 
 Early exposure to cow’s milk 
 Low vitamin D levels 
 Drinking water that contains nitrates 
 Early (before 4 months) or late ( after 7 months) introduction of cereal and 
gluten into a baby’s diet 
 Having a mother who had preeclampsia during pregnancy 
 Being born with jaundice. 
2.6.3 RISK FACTORS FOR TYPE 2 DIABETES  
 Obesity 
 Age 
 Family history of diabetes 
 History of gestational diabetes (diabetes during pregnancy) 
 High blood pressure(˃130/80mm/Hg) 
 Impaired glucose metabolism 
 Physical inactivity 
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 Race/ethnicity- African Americans, Hispanic/ Latino Americans, American 
Indians and some Asian Americans and Native Hawaiians/Pacific Islanders 
are particularly at high risk. 
2.7 DIAGNOSIS OF DIABETES MELLITUS38,39 
The diagnosis of the diabetes is an asymptomatic subject should never be made 
on the basis of a single abnormal blood glucose value. For the asymptomatic person, at 
least one additional plasma blood glucose tolerance test result with a value in the 
diabetic range is essential, either fasting, from a random sample, or from the oral 
glucose tolerance test (OGTT). If such sample fails to confirm the diagnosis of diabetes 
mellitus, it will be usually be advisable to maintain surveillance with periodic retesting 
until the diagnostic situation becomes clear. In these circumstances, the clinician should 
take into consideration such additional factors as ethnicity, family history, age, adiposity, 
and concomitant disorders, before deciding on a diagnostic or therapeutic course of 
action. An alternative to blood glucose estimation, the OGTT has long been sought to 
simplify the diagnosis of diabetes. Glycated haemoglobin, reflecting average glycaemia 
over a period of weeks, was thought to provide such a test. Although in certain cases it 
gives equal or almost equal sensitivity and specificity to glucose measurement, it is not 
available in many parts of the world and is not well enough standardised for its use to 
be recommended at this time.                                                                                                                      
2.7 DIAGNOSTIC CRITERIA38,39 
The clinical diagnosis of diabetes is often prompted by symptoms such as 
increased thirst and urine volume, recurrent infections, unexplained weight loss and in 
severe cases drowsiness and coma; high levels of glycosuria are usually present. A 
single blood glucose estimation is excess of the diagnostic values indicated it and also 
defines levels of blood glucose below which a diagnosis of diabetes is unlikely in non 
pregnant individuals. For clinical purposes, an OGTT (Oral glucose Tolerance Test) only 
be considered to establish diagnostic status if casual blood glucose values lie in the 
uncertain range between the levels that establish or exclude diabetes and fasting blood 
glucose levels are below those which establish the diagnosis of the diabetes. If an 
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OGTT is performed, it is sufficient to measure the blood glucose values while fasting 
and at 2 hours after a 75g oral glucose load. For children, the oral glucose load is 
related to body weight: 1.75 g per kg. The diagnostic criteria in children are same as for 
the adults.  
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Table no-2: Diagnosis of types of diabetes mellitus 
Conditions 
Impaired glucose 
tolerance (IGT) 
Diabetes 
mellitus 
Fasting plasma glucose level 
(FPG) 
110mg/dL- 126mg/L ≥126mg/dL 
Postprandial glucose level 
(PPG) 
140 mg/dL- 199mg/dL ≥200 mg/dl 
Glycosylated haemoglobin 
(HbA1c) level 
6 -6.99% ≥7% 
 
2.7.2 DIABETES IN CHILDREN38,39 
Diabetes in children usually presents with severe symptom such as very high 
blood glucose levels, marked glycosuria and ketonuria. In most children the, diagnosis 
is confirmed without delay by blood glucose measurements and treatment is initiated 
immediately often as life-saving measure. An OGTT is neither necessary nor 
appropriate for diagnosis in such circumstances. A small proportion of children and 
adolescents, however present with less severe symptoms and may require fasting blood 
glucose measurement and/or an OGTT for diagnosis.  
2.8 TREATMENT OF DIABETES MELLITUS41 
The backbone of diabetes management is proper diet and regular exercise, 
which have to be individualized. Both could be the only management needed for 
controlling blood glucose in gestational diabetes, IGT and in type 2 diabetes in its early 
phase. Patients with type 2 diabetes may require oral hypoglycaemic agents and /or 
insulin, while type 1 patients need insulin therapy to survive. 
The treatment plan for diabetes may include: 
 Diabetes education 
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 Meal planning and nutritional requirements 
 Exercise 
 Anti-diabetic agents 
 Insulin therapy 
 Management of associated conditions and complications. 
2.8.1 PHARMACOLOGICAL THERAPY16,23,29,42 
When the lifestyle modifications fails, therapeutic methods should be used that 
consists of the following categories:- 
Sulphonyl urea (Secretagogues) 
          Acetohexamide 
          Chlorpropamide 
          Tolbutamide 
          Glibenclamide 
          Glipizide 
          Gliclazide 
          Glimipiride 
Biguanides 
          Metformin 
          Buformin   
Thiazolidinediones  
          Pioglitazone 
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          Rosiglitazone 
          Dual agonist (PPAR) 
          Aleglitazar 
           Muraglitazar 
           Tesaglitazar 
Alpha glycosidase inhibitors 
          Acarbose 
          Voglibose 
          Miglitol 
 Meglitinides 
          Repaglinide 
          Nateglinide 
          Mitiglinide 
          Lixisenatide 
         Taspoglutide 
Dipeptidyl peptidase 4 inhibitors 
          Saxagliptin 
          Sitagliptin 
          Vidagliptin 
SGLT2 Inhibitors 
          Asoartame 
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          Benfluorex 
          Chronimum picolinate 
          Epalrestat 
          Glucomannan 
          Tolrestat 
Oral agents may counteract insulin resistance, improve β- cell glucose sensing 
and insulin secretion or control the rate of intestinal glucose absorption. Combinations 
of oral agents, in particular sulfonylurea plus metformin or thiazolidinediones plus 
metformin, have improved the care of diabetic patients and may be used when 
monotherapy is in effective. 
2.9 PRECLINICAL IN VIVO ANIMAL MODEL OF DIABETES MELLITUS FOR 
SCREENING OF POTENTIAL ANTI-DIABETIC ACTIVITY 
2.9.1 PHARMACOLOGICAL INDUCTION OF DIABETES 
 Alloxan structure and Sterptozotocin43 
               The cytotoxic glucose analogues alloxan and sterptozotocin are the most 
prominent diabetogenic chemical agents in experimental diabetes research. While the 
mechanism of the selectivity of pancreatic beta cell toxicity is identical, the mechanism 
of the cytotoxic action of the two compounds are different. Both are selectively toxic to 
beta cells because they preferentially accumulate in beta cells as glucose analogues 
through uptake via the GLUT2 glucose transporter. Both compounds are cytotoxic 
glucose analogues. While the mechanism of cytotoxic action of the two compounds is 
different, the mechanism of the selectivity of the beta cell action is identical. 
2.9.2 Alloxan induced diabetes44 
               Alloxan (2, 4, 5, 6- tetra oxy pyrimidine; 2, 4, 5, 6-pyrimidinetetrone) is an 
oxygenated pyrimidine derivative which is present as alloxan hydrate in aqueous 
solution. Brugnatelli originally isolated alloxan in 1818 and the name is given by Wohler 
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and Liebig in 1838. Moreover, the compound was discovered by von Liebig and Wohler 
in 1828 and has been regarded as one of the oldest named organic compounds that 
exist. The name alloxan emerged from the merging of two words, i.e., allantoin and 
oxaluric acid. Allantoin is a product of uric acid excreted by the foetus in the allantoin 
and oxaluric acid has been derived from oxalic acid and urea that is found in urine. 
Additionally the alloxan model of diabetes induction was first described in rabbit by 
Dunn, Sheehan and McLetchie in 1943. Alloxan is originally prepared by the oxidation 
of uric acid by nitric acid. The monohydrate is simultaneously prepared by oxidation of 
barbituric acid by chromium trioxide. 
               Alloxan exerts its diabetogenic action when it is administered parentrally; 
intravenously, intraperitoneally or subcutaneously. The dose of alloxan required for 
inducing diabetes depends on the animal species, route of administration and nutritional 
status. Human islets are considerably more resistant to alloxan than those of the rat and 
mouse. The most frequently used intravenous dose of this drug to induce diabetes in 
rats is 65 mg/kg b.w. when alloxan is given intraperitoneally or subcutaneously its 
effective dose must be 2-3 times higher. Fasted animals are more susceptible to 
alloxan, whereas increased blood glucose provides partial protection. 
2.9.4 STREPTOZOTOCIN 
 
Fig no-4: 2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-β-
D-glucopyranose 
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 Sterptozotocin (STZ) (2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-
β-D-glucopyranose) is synthesized by Streptomycetes achromogenes and is used to 
induce both insulin-dependent and non-insulin-dependent diabetes mellitus (IDDM and 
NIDDM respectively).The range of the STZ dose is not as narrow as in the case of 
alloxan. It is a naturally occurring chemical that is particularly toxic to the insulin- 
producing beta cells of the pancreas in mammals. The frequently used single 
intravenous dose in adult rats to induce IDDM is between 40 and 60 mg/kg b.w. But 
higher doses are also used22. STZ is also efficacious after intraperitoneal administration 
of a similar or higher dose, but single dose below 40 mg/kg b.w. may be ineffective. For 
instance, when 50 mg/kg b.w. STZ are injected intravenously to fed rats, blood glucose 
(determined 2 weeks after treatment) can reach about 15mM. ). STZ may also be given 
in multiple low doses. Such treatment is used predominantly in the mouse and the 
induction of IDDM is mediated by the activation of immune mechanisms. However, that 
the non- specific activation of the immune system via complete Freund's adjuvant prior 
to STZ injections allows to reduce its diabetogenic dose even in the rat. NIDDM can 
easily be induced in rats by intravenous or intraperitoneal treatment with 100 mg/kg 
b.w.45 
2.9.5 Usage of STZ for diabetes mellitus 
 Sterptozotocin is approved by the U.S food and drug administration (FDA) for 
treating metastatic cancer of the pancreatic islet cells. Since it carries a substantial risk 
of toxicity and rarely cures the cancer, its use is generally limited to patients whose 
cancer cannot be removed by surgery. In these patients, sterptozotocin can reduce the 
tumour size and reduce symptoms (especially hypoglycaemia due to excessive insulin 
secretion by insulinomas). A typical dose is 500 mg/m²/day by intravenous injection, for 
5 days, repeated every 4-6 weeks. 
 Due to its high toxicity to beta cells, in scientific research, sterptozotocin has also 
been long used for inducing insulitis and diabetes on experimental animals. 
  REVIEW OF LITERATURE 
 
DEPARTMENT OF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE Page 41 
 
2.9.6 MECHANISM OF STREPTOZOTOCIN46,47 , 48, 49 
Sterptozotocin is a nitrosamine glucosamine- nitrosourea. As with other alkylating 
agents in the nitrosourea class, it is toxic to cells by causing damage to the DNA, 
though other mechanisms may also contribute. DNA damage induces activation of poly 
ADP- ribosylation, which is likely more important for diabetes induction than DNA 
damage itself. Sterptozotocin is similar enough to glucose to be transported into the cell 
by the glucose transport protein GLUT2, but is not recognised by the other glucose 
transporters. This explains its relative toxicity to beta cells, since these cells have 
relatively high levels of GLUT 2. 
STZ is taken up by pancreatic B cells via glucose transporter GLUT2. A reduced 
expression of GLUT2 has been found to prevent the diabetogenic action of STZ 
observed that STZ itself restricts GLUT2 expression in vivo and in vitro when 
administered in multiple doses. Intracellular action of STZ results in changes of DNA in 
pancreatic B cells comprising its fragmentation. Recent experiments have proved that 
the main reason for the STZ-induced B cell death is alkylation of DNA. The alkylating 
activity of STZ is related to its nitrosourea moiety, especially at the O6 position of 
guanine. After STZ injection to rats, different methylated purines were found in tissues 
of these animals. 
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Fig. no-5: Mechanism of action of streptozotocin 
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2.9.7 OTHER DIABETOGENIC AGENTS 
 1. Dehydroascorbic acid 650mg/kg for three days in rat 
 2. Dehydroisoascorbic acid 1.5 mg/kg in rat 
 3. Dehydroglucoascorbic acid 3.5-3.9 gm/kg in rat 
 4. Methyl alloxan 53 mg/kg in rat 
 5. Ethyl alloxan 53-130 mg/kg in rat 
 6. Oxime and dithizone 53 mg/kg in rabbit 
 7. Sodium Diethyldithiocarbonate 0.5-1 gm/kg in rabbit 
 8. Potassium xanthate 200-350 mg/kg in rabbit 
 9. Uric acid 1 gm/kg in rabbit 
 
Table-3: THE SCIENTIFICALLY DOCUMENTED LIST OF MEDICINAL PLANTS 
EXHIBITING ANTI-DIABETIC ACTIVITY 
S. 
No
. 
NAMES OF THE PLANTS 
AND FAMILY 
PARTS 
USED 
TYPES  OF 
PLANT 
EXTRACT 
ANIMAL 
MODEL 
R
e
fe
re
n
c
e
 
1 
Artemesia sephaerocephala 
krasch (Asteraceae) 
Seeds Aqueous Rats (alx) 50 
2 
Eugenia jambolana 
(Myrteaceae) 
Fruits 
Aqueous and 
ethanolic 
Rats (alx) 51 
3 
Fius microcarpa 
(Moraceae) 
Leaves Ethanolic Rats (alx) 52 
4 
Artanema sesamiodes 
(Scophuilariaceae) 
Aerial parts Methanolic Rats (stz) 53 
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5 
Cotu pictus 
(Zingiberaceae) 
Leaves Aqueous Rats (stz) 54 
6 
Phyllanthus rheediii 
(Euphorbiaceae) 
Whole 
plant 
Ethanolic Rats (stz) 55 
7 
Justicia beddomei 
(Acanthaceae) 
Leaves 
Chloroform, 
ethanolic 
Rats (alx) 56 
8 
Nymphaea stellata 
(Nymphaeaceae) 
Flowers Hydroethanolic Rats (alx) 57 
9 
Ichnocarpus frutescens 
(Apocynaceae) 
Roots Aqueous Rats (stz) 58 
10 
Salvadora oleoides 
(Salvadoraceae) 
Stems, 
leaves 
Ethanolic Rats (alx) 59 
11 
Adathoda zeylanica 
(Acanthaceae) 
Leaves 
Hexane, 
methanolc 
Rats (alx) 60 
12 
Berberis aristata  
(Beriberidaceae) 
Roots 
Ethanolic,chlor
oform,petroleu
m ether 
Rats (alx) 61 
13 
Cassia glauca  linn. 
(Caesalpiniaceae) 
Leaves 
Petroleum 
ether, 
choloroform,ac
etone, 
methanolic 
Rats (stz) 62 
14 
Gymnema sylvestre 
(Asclepiadaceae) 
Leaves Aqueous Rats (alx) 63 
15 
Tinospora cordifolia 
(Menipermacadeae) 
Stem 
Aqueous and 
ethanolic 
 
Rats (stz) 64 
17 
Neolamarckia cadamba 
(Rubiaceae) 
Stem, bark Ethanolic Rats (alx) 65 
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18 
Barleria prionitis 
(Acanthaceae) 
Leaves, 
roots 
Ethanolic Rats (alx) 66 
19 
Pongamiapinnata 
(Leguminosea) 
Leaves 
Ethanolic,chlor
oform,petroleu
m ether 
Rats (alx) 67 
20 
Cathranthus roseus 
(Apocynaceae) 
Leaves 
Dichlorometha
ne and 
methanolic 
Rats (alx) 68 
21 
Cathranthus roseus 
(Apocynaceae) 
Whole 
plant 
Ethanolic Rats (alx) 69 
22 
Indigofera pulchra 
(Papilionaceae) 
Leaves 
Ethyl acetate, 
n-butanol 
Rats (alx) 70 
23 
Sarcococca saligna 
(Buxaceae) 
Whole 
plant 
Petroleum 
ether, ethyl 
acetate 
Rats (stz) 
 
71 
 
24 
Sphaeranthus indicus 
(Compositae) 
Roots Ethanolic Rats (stz) 72 
25 
Barleria cristata 
(Acanthaceae) 
Seeds Ethanol Rats (alx) 73 
26 
Aniogeissus latifolia 
(Combertaceae) 
Bark Aqueous 
Rats 
(stz,NIN) 
74 
27 
Tabebuia rosea 
(Bignoniaceae) 
Leaves Methanol Rats(alx) 36 
28 
Kigelia Africana 
(Bignoniaceae  
Leaves Methanol Rats (alx) 36 
29 
Vitex doniana 
(Verbanaceae) 
Leaves Aqueous Rats (alx) 75 
30 
Cinchona calisaya 
(Rubiaceae) 
Bark Aqueous Rats (alx) 
 
75 
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31 
Tetracera indica 
(Dilleniaceae) 
Leaves 
Aqueous and 
methanol 
Rats (alx) 76 
32 
Phyllanthus amarus 
(Pyhllanthaceace 
Leaves Methanol Mice (alx) 77 
33 
Rosmarinus officinalis 
(Lamiaceae) 
Leaves Aqueous Rats (stz) 
 
78 
34 
Emblica officinalis 
(Pyhllanthaceace) 
Seeds Methanol Rats (stz) 
 
79 
35 
Pueraria tuberose 
(Fabaceae) 
Tubers Ethyl aceate Rats (alx) 80 
36 Anogeissus acuminate Bark Methanol Mice (alx) 81 
37 
Corallocarpus epigaeus 
(Cucurbitaceae) 
Rhizomes Ethanol Rats (alx) 82 
38 
Fumaria parviflora lam 
(Fumariaceae) 
Aerial parts Methanol Rats (stz) 83 
39 
Vernonia cinerea 
(Asteraceae) 
Bark and 
leaves 
Methanol Rats (alx) 84 
40 
Calamus erectus 
(Arecaceae) 
Fruit Methanol Rats (stz) 85 
41 
Cassia kleinii 
(Caesalpiniaceae) 
Leaf, 
roots 
Aqueous, 
ethanolic 
Rats (alx) 86 
42 
Ficus hispida 
(Moraceae) 
bark ethanolic Rats (alx) 87 
43 
Lycium barbarum 
(Solanaceae) 
Fruits Aqueous 
Rabbits 
(alx) 
88 
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PLANT DESCRIPTION89 
Botanical Name 
Mallotusphilippensis Muel.Arg. 
Common Name 
Kamala Dye Tree 
 
 
 
 
 
 
Fig. No 6: Whole plant of Mallotus philippensis Muell.Arg. 
Vernacular Names 
English : Kamala Tree 
Hindi : Sindur, Rohini 
Bengali : Kamalagundi 
Gujarathi : Kapilo 
Malayalam : KuranguManjal 
Marathi : Shindur 
Punjabi : Kumila 
Tamil : Kungumam 
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Telugu : Kunkuma 
Assami : Gangai 
Oriya : Bosonto-gundi 
TAXONAMY                          
Kingdom : Plantae 
Subkingdom : Tracheobionta 
Superdivision 
Division     
: 
: 
Spermatophyta 
Magnoliopsida 
Class     : Rosidae 
Order    : Euphobiales 
Family : Euphorbiaceae 
Genus     : Mallotus 
Species   : Philippensis 
 
BOTANY 
Leaves are alternate and simple, more or less leathery, ovate to lanceolate, cuneate to 
rounded with two glands at base. Leaves are mostly acute or acuminate at apex, 
conspicuously 3-nerved, hairy and reddish glandular beneath, petiole size 1–4 cm long, 
puberulous and reddish-brown in colour. Male flowers in terminal and axillary position, 
2–10 cm long, solitary or fascicled paniculates spikes, each flowers are with numerous 
stamens, small; female flowers have spikes or slender racemes, each flower with a 
stellate hairy, 3 celled ovary with 3 papillose stigmas. Fruit is a depressed-globose; 3-
lobed capsule; 5, 7 mm, and 10 mm; stellate; puberulous; with abundant orange or 
reddish glandular granules; 3-seeded . Seeds are subglobose and black in colour and 
4 mm across. 
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Distribution 
Mallotus philippensis Muell.Arg. (Family: Euphorbiaceae) is a branched herb found in 
hills of southern districts of Tamilnadu and kerala. It is also common in America and 
occurs in Eastern Africa and East India. 
Parts Used 
Fruits 
Chemical Constituents 
 Major phytochemicals present in this genus contain different natural compounds, 
mainly phenols, diterpenoids, steroids, flavonoids, cardenolides, triterpenoids, 
coumarin, isocoumarins, and many more to discover. Present knowledge about this 
endangered species of medicinal plant is still limited with respect to its phytochemistry 
and biological activity.One of the major chemical constituent, that is, rottlerin of M. 
philippinensis, is listed below with its chemical structure and its major biological 
activities along with other phytochemicals 
Cardenolides 
(Corotoxigenin,L-rhamnoside, corogl-aucigenin and L-rhamnoside.) 
Steroids 
(β-Sitosterol.) 
Phenolic Compounds 
 (Bergenin, Kamalachalcone A.,Kamalachalcone B.,Mallotophilippen 
A.,Mallotophilippen B.,Mallotophilippen C.,Mallotophilippen D. and Mallotophilippen E) 
 
phloroglucinol derivatives 
 (Rottlerin, Isoallorottlerin and Isorottlerin.) 
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Triterpenoids 
 (Betulin-3-acetate,Friedelin,Acetylaleuritolic acid’γb-Acetoxy-22b-hydroxyolean-
18-ene and α-Amyrin.) 
 
Properties and Uses 
According to Ayurveda, leaves are bitter, cooling, and appetizer. All parts of plant like 
glands and hairs from the capsules or fruits are used as heating, purgative, 
anthelmintic, vulnerary, detergent, maturant, carminative, Anti-diabetic,90 and alexiteric 
and are useful in treatment of bronchitis, abdominal diseases, and spleen enlargement, 
and if taken with milk or curd (yoghurt), it can be quite useful for expelling tapeworms . 
Kamala or Kampillakah is also used as an oral contraceptive. The powder and a few 
other parts of Kamala are also used in external applications to promote the healing of 
ulcers and wounds. They are used to treat parasitic affections of the skin like scabies, 
ringworm, and herpes. 
Earlier Work Done On Mallotus philippensis Muell.Arg. 
 Cuong NX et al. have studied ‘’A new lignan dimer from Mallotus philippensis’’. A 
new lignan dimer, bilariciresinol (1), was isolated from the leaves of Mallotus 
philippensis, along with platanoside (2), isovitexin (3), dihydromyricetin (4), 
bergenin (5), 4-O-galloylbergenin (6), and pachysandiol A (7). Their structures 
were elucidated by spectroscopic experiments including 1D and 2D NMR and 
FTICR-MS91. 
 Chan TK et al. have studied ‘’Anti-allergic actions of rottlerin 
from Mallotus philippensis in experimental mast cell-mediated anaphylactic 
models’’. Allergy is an acquired hypersensitivity reaction of the immune system 
mediated by cross-linking of the allergen-specific IgE-bound high-affinity IgE 
receptors, leading to immediate mast cell degranulation. Rottlerin is an active 
molecule isolated from Mallotus philippensis, a medicinalplant used in Ayurvedic 
Medicine System for anti-allergic and anti-helminthic treatments. The present 
  PLANT MONOGRAPH 
 
DEPARTMENT OF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE                               Page  
 
51 
study investigated potential anti-allergic effects of rottlerin in animal models of 
IgE-dependent anaphylaxis and the anti-allergic mechanisms of action of rottlerin 
in mast cells. Anti-allergic actions of rottlerin were evaluated in passive 
cutaneous anaphylaxis and passive systemic anaphylaxis mouse models, and in 
anaphylactic contraction of bronchial rings isolated from sensitized guinea pigs. 
Direct mast cell-stabilizing effect of rottlerin was examined in RBL-2H3 mast cell 
line. Anti-allergic signaling mechanisms of action of rottlerin in mast cells were 
also examined. Rottlerin prevented IgE-mediated cutaneous vascular 
extravasation, hypothermia, elevation in plasma histamine level and tracheal 
tissue mast cell degranulation in mice in a dose-dependent manner. In addition, 
rottlerin suppressed ovalbumin-induced guinea pig bronchial smooth muscle 
contraction. Furthermore, rottlerin concentration-dependently blocked IgE-
mediated immediate release of ȕ-hexosaminidase from RBL-2H3 mast cells. 
Rottlerin was found to inhibit IgE-induced PLCȖ1 and Akt phosphorylation 
production of IP3 and rise in cytosolic Ca+2  level in mast cells. We report here for 
the first time that rottlerin possesses anti-allergic activity by blocking IgE-induced 
mast cell degranulation, providing a foundation for developing rottlerin for the 
treatment of allergic asthma and other mast cell-mediated allergic disorders.92 
 Hong Q et al. have studied ‘’Anti-tuberculosis compounds 
from Mallotus philippensis’’. Bioassay-directed fractionation of the organic extract 
of Mallotus philippensis gave five compounds (1-5), the most active of which 
against Mycobacterium tuberculosis was a new compound, 8-cinnamoyl-5,7-
dihydroxy-2,2-dimethyl-6-geranylchromene (1) for which the name 
mallotophilippen F is suggested. Compound (2), 8-cinnamoyl-2,2-dimethyl-7-
hydroxy-5-methoxychromene, was isolated from a natural source for the first 
time, while the remaining three compounds, rottlerin (3), 
isoallorottlerin=isorottlerin (4) and the so-called "red compound," 8-cinnamoyl-
5,7-dihydroxy-2,2,6-trimethylchromene (5), had been isolated previously from 
this plant. All compounds were identified by analysis of their spectra including 
2D-NMR, which was used to correct the literature NMR spectral assignments of 
compounds 2-4. The C-13 NMR of 5 is reported for the first time.93 
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 Kulkarni RR et al. have studied ‘’Antifungal dimericchalcone derivative 
kamalachalcone E from Mallotus philippensis’’. From the red coloured extract 
(Kamala) prepared through acetone extraction of the fresh whole uncrushed 
fruits of Mallotus philippensis, one new dimericchalcone (1) along with three 
known compounds 1-(5,7-dihydroxy-2,2,6-trimethyl-2H-1-benzopyran-8-yl)-3-
phenyl-2-propen-1-one (2), rottlerin (3) and 4'-hydroxyrottlerin (4) were isolated. 
The structure of compound 1 was elucidated by 1D and 2D NMR analyses that 
included HSQC, HMBC, COSY and ROESY experiments along with the literature 
comparison. Compounds 1-4 were evaluated for antifungal activity against 
different human pathogenic yeasts and filamentous fungi. The antiproliferative 
activity of the compounds was evaluated against Thp-1 cell lines. Compounds 1 
and 2 both exhibited IC50 of 8, 4 and 16 μg/mL against Cryptococcus 
neoformans PRL518, C. neoformans ATCC32045 and Aspergillusfumigatus, 
respectively. Compound 4, at 100 μg/mL, showed 54% growth inhibition of Thp-1 
cell lines.94 
 Khan H et al. have studied ‘’Antioxidant and Antiplasmodial Activities of Bergenin 
and 11-O-Galloylbergenin Isolated from Mallotus philippensis’’. Two important 
biologically active compounds were isolated from Mallotus philippensis. The 
isolated compounds were characterized using spectroanalytical techniques and 
found to be bergenin (1) and 11-O-galloylbergenin (2). The in vitro antioxidant 
and antiplasmodial activities of the isolated compounds were determined. For the 
antioxidant potential, three standard analytical protocols, namely, DPPH radical 
scavenging activity (RSA), reducing power assay (RPA), and total antioxidant 
capacity (TAC) assay, were adopted. The results showed that compound 2 was 
found to be more potent antioxidant as compared to 1. Fascinatingly, compound 
β displayed better EC50 results as compared to α-tocopherol while being 
comparable with ascorbic acid. The antiplasmodial assay data showed that both 
the compound exhibited good activity against chloroquine sensitive strain of 
Plasmodium falciparum (D10) and IC50 values were found to be less than 8 μM. 
The in silico molecular docking analyses were also performed for the 
determination of binding affinity of the isolated compounds using P. falciparum 
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proteins PfLDH and Pfg27. The results showed that compound 2 has high 
docking score and binding affinity to both protein receptors as compared to 
compound 1. The demonstrated biological potentials declared that compound 2 
could be the better natural antioxidant and antiplasmodial candidate.95 
 Gangwar M et al. have studied ‘’Antioxidant capacity and radical scavenging 
effect of polyphenol rich Mallotus philippensis fruit extract on human 
erythrocytes: an in vitro study’’. Mallotus philippensis is an important source of 
molecules with strong antioxidant activity widely used medicinal plant. Previous 
studies have highlighted their anticestodal, antibacterial, wound healing activities, 
and so forth. So, present investigation was designed to evaluate the total 
antioxidant activity and radical scavenging effect of 50% ethanol fruit glandular 
hair extract (MPE) and its role on Human Erythrocytes. MPE was tested for 
phytochemical test followed by its HPLC analysis. Standard antioxidant assays 
like DPPH, ABTS, hydroxyl, superoxide radical, nitric oxide, and lipid 
peroxidation assay were determined along with total phenolic and flavonoids 
content. Results showed that MPE contains the presence of various 
phytochemicals, with high total phenolic and flavonoid content. HPLC analysis 
showed the presence of rottlerin, a polyphenolic compound in a very rich 
quantity. MPE exhibits significant strong scavenging activity on DPPH and ABTS 
assay. Reducing power showed dose dependent increase in concentration 
absorption compared to standard, Quercetin. Superoxide, hydroxyl radical, lipid 
peroxidation, nitric oxide assay showed a comparable scavenging activity 
compared to its standard. Our finding further provides evidence that Mallotus fruit 
extract is a potential natural source of antioxidants which have a protective role 
on human Erythrocytes exhibiting minimum hemolytic activity and this justified its 
uses in folklore medicines.96 
 Khan M et al. have studied ‘’Hexane soluble extract of Mallotus philippensis 
Muell.Arg. root possesses anti-leukaemic activity’’. Root extract of 
M. philippensis was initially extracted in organic solvents, hexane, ethyl acetate, 
and n-butanol. The hexane extract showed highest toxicity against p53-deficient 
HL-60 cells (IC50 1.5 mg dry roots equivalent/ml medium) after 72 h and 
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interestingly, inhibition of cell proliferation was preceded by the upregulation of 
the proto-oncogenes Cdc25A and cyclin D1 within 24 h. The hexane extract 
induced 18% apoptosis after 48 h of treatment. Chemical composition of the 
hexane extract was analyzed by GC-MS and the 90% fragments were matched 
with polyphenolic compounds. The present study confirms that the hexane 
fraction of M. philippensis root extract possesses anti-leukemic activity in HL-60 
cells. The polyphenols were the main compounds of the hexane extract that 
inhibited proliferation and induced apoptosis.97 
 Gangwar M et al. have studied ‘’In-vitro scolicidal activity of Mallotus philippensis 
Muell.Arg. fruit glandular hair extract against hydatid cyst 
Echinococcusgranulosus’’. To investigate new scolicidal agent from natural 
resources to cope with the side effects associated with synthetic drugs in 
Echinococcosis. The scolicidal potential of methanolic fruit powder extract (10 
and 20 mg/mL) of Mallotus philippensis was investigated. Viability of 
protoscoleces was confirmed by trypan blue exclusion method, where mortality 
was observed at concentration of 10 and 20 mg/mL in 60 min treatment against 
Echinococcusgranulosus (E. granulosus), under in-vitro conditions with reference 
to the known standard drug Praziquantel. At concentration 10 and 20 mg/mL, the 
mortality rate was observed 97% and 99% respectively for 60 min treatment; 
while up to 93% mortality was observed with 20 mg/mL for only 10 min treatment. 
The concentration above 20 mg/mL for above 2 h showed 100% mortality, 
irrespective of further incubation. As compared with the standard anti-parasitic 
drug Praziquantel our extract has significant scolicidal activity with almost no 
associated side effects.98 
  Goel RK et al. have studied ‘’Mallotus philippensis Muell.Arg. (Euphorbiaceae): 
ethnopharmacology and phytochemistry review. Mallotus philippensis Muel.Arg”. 
(Euphorbiaceae) are widely distributed perennial shrub or small tree in tropical 
and subtropical region in outer Himalayas regions with an altitude below 1,000 m 
and are reported to have wide range of pharmacological 
activities. Mallotus philippensis species are known to contain different natural 
compounds, mainly phenols, diterpenoids, steroids, flavonoids, cardenolides, 
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triterpenoids, coumarins, isocoumarins, and many more especially phenols; that 
is, bergenin, Malloto philippensis, rottlerin, and isorottlerin have been isolated, 
identified, and reported interesting biological activities such as antimicrobial, 
antioxidant, antiviral, cytotoxicity, antioxidant, anti-inflammatory, 
immunoregulatory activity protein inhibition against cancer cell. We have selected 
all the pharmacological aspects and toxicological and all its biological related 
studies. The present review reveals that Mallotus philippensis is a valuable 
source of medicinally important natural molecules and provides convincing 
support for its future use in modern medicine. However, the existing knowledge is 
very limited about Mallotus philippensis and its different parts like steam, leaf, 
and fruit. Further, more detailed safety data pertaining to the acute and subacute 
toxicity and cardio- and immunotoxicity also needs to be generated for crude 
extracts or its pure isolated compounds. This review underlines the interest to 
continue the study of this genus of the Euphorbiaceae.99 
 Furumoto T et al. have studied ‘’Mallotus philippensis bark extracts promote 
preferential migration of mesenchymal stem cells and improve wound healing in 
mice’’. In the present study, we report the effects of the ethanol extract 
from Mallotus philippensis bark (EMPB) on mesenchymal stem cell (MSC) 
proliferation, migration, and wound healing in vitro and in a mouse model. 
Chemotaxis assays demonstrated that EMPB acted an MSC chemoattractant 
and that the main chemotactic activity of EMPB may be due to the effects of 
cinnamtannin B-1. Flow cytometric analysis of peripheral blood mononuclear 
cells in EMPB-injected mice indicated that EMPB enhanced the mobilization of 
endogenous MSCs into blood circulation. Bioluminescent whole-animal imaging 
of luciferase-expressing MSCs revealed that EMPB augmented the homing of 
MSCs to wounds. In addition, the efficacy of EMPB on migration of MSCs was 
higher than that of other skin cell types, and EMPB treatment improved of wound 
healing in a diabetic mouse model. The histopathological characteristics 
demonstrated that the effects of EMPB treatment resembled MSC-induced tissue 
repair. Taken together, these results suggested that EMPB activated the 
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mobilization and homing of MSCs to wounds and that enhancement of MSC 
migration may improve wound healing.100 
 Gautam MK et al. have studied ‘’Mallotus philippensis Muell.Arg. fruit glandular 
hairs extract promotes wound healing on different wound model in rats’’. The 
study includes acute toxicity and wound healing potential of 50% ethanol extract 
of MP fruit glandular hair (MPE). MPE (200 mg/kg) was administered orally, once 
daily for 10 days (incision and dead space wound) and 22 days (excision wound). 
MPE was found safe when given to ratsupto 10 times of optimal effective dose. 
Wound breaking strength (WBS) in Incision wound and rate of contraction, period 
of epithelization and scar area in Excision wound were evaluated. Granulation 
tissue free radicals (nitric oxide and lipid peroxidation), antioxidants (catalase, 
superoxide dismutase, and reduced glutathione), acute inflammatory marker 
(myeloperoxidase), connective tissue markers (hydroxyproline, hexosamine, and 
hexuronic acid), and deep connective tissue histology were studied in Dead 
space wound. MPE significantly increased WBS and enhanced wound 
contraction, and decreased both epithelization period and scar area compared 
with control group. MPE was found to decrease free radicals (50.8 to 55.2%, 
P<0.001) and myeloperoxidase (44.0%, P<0.001) but enhanced antioxidants 
(41.1 to 54.5%, P<0.05 to P<0.001) and connective tissue markers (39.5 to 
67.3%, P<0.05 to P<0.01). Histopathological evaluation revealed more density of 
collagen formation with minimal inflammatory cells in deeper tissues. Thus, the 
study revealed Mallotus philippensis fruit hair extract, safe and effective in wound 
healing and the healing effects seemed to be due to decrease in free radical 
generated tissue damage, promoting effects on antioxidant status and faster 
collagen deposition as evidenced biochemically and histology.101 
 Oyedemi BO et al. have studied ‘’Novel R-plasmid conjugal transfer inhibitory 
and antibacterial activities of phenolic compounds from Mallotus 
philippensis Mull.Arg’’. Antimicrobial resistance severely limits the therapeutic 
options for many clinically important bacteria. In Gram-negative bacteria, 
multidrug resistance is commonly facilitated by plasmids that have the ability to 
accumulate and transfer refractory genes amongst bacterial populations. The aim 
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of this study was to isolate and identify bioactive compounds from the 
medicinal plant Mallotus philippensis Mull.Arg. with both direct antibacterial 
properties and the capacity to inhibit plasmid conjugal transfer. A chloroform-
soluble extract of M. philippensis was subjected to bioassay-guided fractionation 
using chromatographic and spectrometric techniques that led to the isolation of 
the known compounds rottlerin [5,7-dihydroxy-2,2-dimethyl-6-(2,4,6-trihydroxy-3-
methyl-5-acetylbenzyl)-8-cinnamoyl-1,2-chromene] and the red compound (8-
cinnamoyl-5,7-dihydroxy-2,2,6-trimethylchromene). Both compounds were 
characterised and elucidated using one-dimensional and two-dimensional 
nuclear magnetic resonance (NMR). Rottlerin and the red compound showed 
potent activities against a panel of clinically relevant Gram-positive bacteria, 
including meticillin-resistant Staphylococcus aureus (MRSA). No significant direct 
activities were observed against Gram-negative bacteria. However, both rottlerin 
and the red compound strongly inhibited conjugal transfer of the plasmids 
pKM101, TP114, pUB307 and R6K amongst Escherichia coli at a subinhibitory 
concentration of 100mg/L. Interestingly, despite the planar nature of the 
compounds, binding to plasmid DNA could not be demonstrated by a DNA 
electrophoretic mobility shift assay. These results show that rottlerin and the red 
compound are potential candidates for antibacterial drug lead development. 
Further studies are needed to elucidate the mode of inhibition of the conjugal 
transfer of plasmids.102 
 Chhiber N et al. have studied ‘’Rottlerin, a polyphenolic compound from the fruits 
of Mallotus phillipensis Mull.Arg.’’ impedes oxalate/calcium oxalate induced 
pathways of oxidative stress in male wistar rats. Oxalate and/or calcium oxalate, 
is known to induce free radical production, subsequently leading to renal 
epithelial injury. Oxidative stress and mitochondrial dysfunction have emerged as 
new targets for managing oxalate induced renal injury. Hyperoxaluria was 
induced by administering 0.4% ethylene glycol and 1% ammonium chloride in 
drinking water to male wistar rats for 9 days. Rottlerin was administered 
intraperitoneally at 1mg/kg/day along with the hyperoxaluric agent. Prophylactic 
efficacy of rottlerin to diminish hyperoxaluria induced renal dysfunctionality and 
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crystal load was examined along with its effect on free radicals generating 
pathways in hyperoxaluric rats. 0.4% ethylene glycol and 1% ammonium chloride 
led to induction of hyperoxaluria, oxiadtive stress and mitochondrial damage in 
rats. Rottlerin treatment reduced NADPH oxidase activity, prevented 
mitochondrial dysfunction and maintained antioxidant environment. It also 
refurbished renal functioning, tissue integrity and diminished urinary crystal load 
in hyperoxaluric rats treated with rottlerin. Thus, the present investigation 
suggests that rottlerin evidently reduced hyperoxaluric consequences and the 
probable mechanism of action of this drug could be attributed to its ability to 
quench free radicals by itself and interrupting signaling pathways involved in 
pathogenesis of stone formation.103 
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GLIBENCLAMIDE 
 
 
5-chloro-N-[2-[4-(cyclohexylcarbonyl sulfamoyl)phenyl]ethyl]-2-methoxy benzamide 
 
It is an ant diabetic drug in a class of medication known as sulfonyl ureas, closely 
related to sulfonamide antibiotics.104 
Mechanism of action  
The drug works by binding to and inhibiting the ATP-sensitive potassium channel 
(KATP) inhibiting regulatory subunit sulfonyl urea receptor 1 in pancreatic beta cells. 
This inhibition causes cell membrane depolarization opening voltage dependent calcium 
channels. This results in an increase in intracellular calcium in the beta cell and 
subsequent stimulation of insulin release105 
Medical use 
Used in the treatment of Diabetes106 
 
  
  SCOPE OF THE PRESENT STUDY 
 
DEPARTMENT OF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE Page 60 
 
SCOPE OF THE PRESENT STUDY 
In the present situation, diabetes is possibly the world’s largest growing 
metabolic disorders and as the knowledge on the heterogenicity of this disorder is 
advanced, the need for more appropriate therapy increases. A number of allopathic 
drugs are used for the anti-diabetic effect like Tolbutamide, metformin, phenformin 
and acarbose which have danger of drug interaction, adverse effects etc. Traditional 
plant medicines are used throughout the world for a range of diabetic presentations. 
There are many medicinal plants known to be used in the treatment of diabetes and 
a number of plants had been screened positively for their anti-diabetic effect. Most of 
these plants were found to belong to the chemical group glycosides, alkaloids and 
flavanoids. 
Diabetes mellitus has to become one of the world’s biggest health problems 
owing to the projected increase in new cases. In India, the prevalence rate of 
diabetes is estimated to be 1-5%. Complications are the major cause of morbidity 
and mortality in diabetes mellitus. 
MallotusPhilippensis Muell.Arg. Fruit is having the anti-diabetic activity. As per 
the literature review, still no anti-diabetic activity has been reported on this plant. 
Hence, this study has been taken to explore the anti-diabetic activity of Mallotus 
Philippensis Muell.Arg. in sterptozotocin induced diabetes in Wistar albino rats. 
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AIM AND OBJECTIVES 
Aim  
 The present investigation was aimed to screen the anti-diabetic activity of 
Mallotus Philippensis  Muell.Arg. on sterptozotocin induced diabetic Wistar albino 
rats. 
Objectives 
The objective of the present study to: 
a. Find out the phytochemical constituents present in the ethanolic extract of the 
whole plant of Mallotus Philippensis  Muell.Arg. 
b. Acute toxicity studies 
c. Evaluation of anti-diabetic activity 
 
 Blood glucose level 
 Glycosylated haemoglobin 
d. Estimation of Serum parameters 
 Total cholesterol level 
 Serum aspartate amino transferace level (AST) 
 Serum alanine amino transferace level (ALT) 
e. Estimation of Oxidative stress parameters 
 Liver malondialdehyde level (MDA)  
f. Estimation of enzymic hepatic antioxidant parameters 
 Liver superoxide dismutase level (SOD) 
 Liver catalase level (CAT) 
 Liver glutathione peroxide level (GPx) 
g. Estimation of non-enzymic anti-oxidant activity 
 Reduced glutathione (GSH) level 
 Ascorbic acid (Vitamin C) level 
 α –tocopherol (Vitamin E) level 
h. Estimation of plasma insulin level 
i. Histopathology of pancreas. 
j. Statistical analysis 
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PLAN OF WORK  
1. Collection of plant. 
2. Authentication of plant, shade drying of the Fruits. 
3. Extraction of plant materials with solvents. 
4. Preliminary phytochemical screening of ethanolic extract of Fruits Mallotus 
Philippensis Muell.Arg. 
5. Evaluation of acute toxicity studies to determine LD50 value 
6. Evaluation of anti-diabetic activity. 
7. Estimation of biochemical parameters. 
8. Study of histopathology of pancreas. 
9. Statistical analysis 
 
  MATERIALS AND METHODS 
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6. MATERIALS AND METHODS 
 
6.1 PLANT MATERIAL 
6.1.1 Collection and authentication, shade drying and granulation of plant 
material 
1. The Fruits of Mallotus Philippensis Muell.Arg. were collected in the month of 
December from, Cherpulassery, Palakkad (Dist), Kerala South India. The plant 
material was taxonomically identified and authenticated by 
Dr.A.Balasubramanian, Director, ABS Botanical conservation, Research & 
Training center, Kaaripatti, Salem.  
6.1.2 Preparation of Extract 
               The Fruits of Mallotus Philippensis Muell.Arg. were dried under shade and 
then powdered with a mechanical grinder. The powder was passed through sieve No 40 
and stored in an airtight container for further use. 
Purification of Solvent 
Ethanol  
          Rectified spirit was soaked in slaked lime overnight and distilled. 
6.1.3 Extraction procedure 
          The coarse Fruit powder was extracted with ethanol by continuous hot percolation 
using soxhlet apparatus. After completion of extraction, extract was filtered and the 
solvent was removed by under reduced pressure. The dried extract was stored in 
desiccators. 
6.1.4 METHOD OF EXTRACTION 
Soxhlet extraction 
Soxhlet extraction is the process of continuous extraction in which the same 
solvent can be circulated through the extractor for several times. This process involves 
in the extraction followed by evaporation of the solvent. The vapours of the solvent are 
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taken to a condenser and the condensed liquid is returned to the drug for continuous 
extraction.  Soxhlet apparatus designed for such continuous extraction consists of a 
body of extractor attached with a side tube and siphon tube. The lower of the extractor 
is attached to distillation flask and the mouth of extractor is fixed to a condenser by the 
standard joints. The powdered crude drug is packed in the soxhlet apparatus directly or 
in a thimble of filter paper or fine muslin cloth. The diameter of the thimble corresponds 
to the internal diameter of the soxhlet extractor.  
6.2 PRELIMINARY PHYTOCHEMICAL SCREENING 
Qualitative Phytochemical Analysis107 
           The ethanolic extract of dried Fruits of crude  Mallotus Philippensis was analyzed 
for the presence of various phytoconstituents. 
A) CARBOHYDRATE TESTS 
1. Molisch’s test 
To the test solution, few drops of α-naphthol was added, then few drops of 
concentrated sulphuric acid was added  through the sides of test tube, purple to 
violet colour ring appeared at the junction, indicated the presence of 
carbohydrates. 
2. Fehling’s test 
To the test solution, equal quantity of Fehling’s A and B were added and heated 
on water bath, brick red precipitate was formed, indicated the presence of 
carbohydrates. 
3. Benedict’s test 
To the test solution, 5ml of Benedict’s reagent was added and heated on water 
bath, red precipitate was formed, indicated the presence of carbohydrates. 
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4. Barfoed’s test 
To 1 ml of the test solution, add 1ml of Barfoed’s reagent was added and heated 
on a water bath, red cupric oxide was formed, presence of monosaccharide. 
5. Test for pentoses 
To the test solution, equal volume of hydrochloric acid and phloroglucinol was 
added and heated, no red colour was produced, indicated the absence of 
pentoses. 
6. Selivanoff’s test (test for ketones) 
To the test solution, crystals of resorcinol and equal volume of concentrated 
hydrochloric acid were added and heated on a water bath, rose colour was 
produced, indicated the presence of ketones. 
B) ALKALOIDS 
1. Dragendroff’s test 
To 1ml of the extract, Dragendroff’s reagent (potassium bismuth iodine solution) 
was added, no reddish brown precipitate was formed, indicated the absence of 
alkaloids. 
2. Wagner’s test 
To 1ml of the extract, Wagner’s reagent (iodine potassium iodide solution) was 
added, no reddish brown precipitate was formed, indicated the absence of 
alkaloids. 
3. Mayer’s test 
To 1 ml of the extract, Mayer’s reagent (potassium mercuric iodine solution) was 
added, no cream colour precipitate was formed, indicated the absence of alkaloids. 
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4. Hager’s test 
To 1 ml of the extract, Hager’s reagent (saturated aqueous solution of picric acid) 
was added, no yellow coloured precipitate was formed, indicated the absence of 
alkaloids.  
5. Tannic acid test 
To the extract tannic acid solution was added, no buff colour precipitate was 
produced, indicated the absence of alkaloids. 
C) GLYCOSIDE TEST 
1. Legal’s test 
The extract in pyridine and sodium nitroprusside solution was added to make it 
alkaline, formation of pink to red colour showed the presence of glycosides. 
2. Baljet’s test 
To 1 ml of the extract, 1 ml of sodium picrate solution was added and the change 
of yellow to orange colour reveals the presence of glycosides. 
3. Borntrager’s test 
 Few ml of dilute sulphuric acid was added to 1 ml of the extract solution. Boiled 
and filtered and then the filtrate was extracted with chloroform. The chloroform 
layer was treated with 1 ml of ammonia. The formation of red colour of the 
ammonical layer showed the presence of anthraquinone glycosides. 
4. Keller killani test 
1. 1gm of powdered drug was extracted with 10ml of 70% alcohol for 2 minutes, 
filtered, the filtrate was added to 10 ml of water and 0.5 ml of strong solution of 
lead acetate and filter, and the filtrate was shaken with 5ml of chloroform. 
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2. The chloroform layer was separated in a porcelain dish and the solvent was 
removed by gentle evaporation. The cooled residue was dissolved in 3 ml of 
glacial acetic acid containing 2 drops of 5% ferric chloride solution. 
The solution was carefully transferred to the surface of 2ml of 
concentrated sulphuric acid. A reddish brown layer formed at the junction of the 
two liquids and the upper layer slowly became bluish green, darkening with 
standing. 
D) TEST FOR SAPONINS 
Foam test 
 Small quantity of alcoholic extract was taken and 20ml of distilled water 
was added and shaked in a graduated cylinder for 15 minutes length wise. No 
Layer of foam, indicated the absence of saponins. 
 
E) TEST FOR FLAVANOIDS 
1. Shinoda’s test 
 To the test solution, few magnesium turnings were added and 
concentrated hydrochloric acid was added drop wise, pink scarlet, crimson red or 
occasionally green to blue colour appeared after few minutes indicating the 
presence of flavanoids. 
2. Alkaline reagent test 
To the test solution, few drops of sodium hydroxide solution was added, 
intense yellow colour was formed which turned colourless on addition of few 
drops of dilute acid indicating presence of flavanoids. 
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3. Zinc hydrochloride test  
To the test solution, a mixture of zinc dust and concentrated hydrochloric 
acid were added. It gave red colour after few minutes showing the 
presence of flavanoids. 
 
F) TEST FOR TANNINS 
1. Ferric chloride test 
To the test solution, ferric chloride solution was added, green colour 
appeared showing the presence of condensed tannins. 
2. Phenazone test 
To the test solution, 0.5 grams of sodium phosphate was added, warmed 
and filtered. To the filtrate 2% phenazone solution was added, bulky precipitate 
was formed which was often coloured, indicating the presence of tannins. 
3. Gelatin test 
To the test solution, 1% gelatine solution containing 10% sodium chloride 
was added. Precipitate was formed, indicating the presence of tannins. 
4. Test for Catechin 
Match stick was dipped in the test solution, it was dried and lastly 
moistened with concentrated hydrochloric acid. Then the stick was warmed 
near to flame. The colour of the wood changed to pink due to phloroglucinol. 
(Phloroglucinol was formed when catechins were treated with acids), indicating 
the presence of tannins. 
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TEST FOR PROTEINS 
1. Warming test 
The test solution was heated in a boiling water bath, coagulation was 
observed, indicating the presence of proteins. 
2. Test with Trichloroacetic acid 
To the test solution trichloroacetic acid was added, precipitate was 
formed, indicating the presence of proteins 
3. Biuret test 
To the test solution (2ml), Biuret (2ml) was added, violet colour was 
produced, indicating the presence of proteins. 
 
4. Xanthoproteic test 
 5ml of the test solution, 1ml of concentrated nitric acid was added and 
boiled, yellow precipitate was formed. After cooling it, 40% sodium hydroxide 
solution was added orange colour was formed, indicating the presences of 
proteins. 
G) TEST FOR AMINO ACIDS 
1. Million’s test 
To the test solution, about 2ml of Million’s reagent was added, white 
precipitate was obtained indicating the presence of amino acids. 
2. Ninhydrin test 
To the test solution, ninhydrin solution was added, boiled, violet colour 
was produced indicating the presence of amino acid. 
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H)  TEST FOR STEROIDS AND TRITERPENOIDS 
1. Libermann-Buchard test 
The extract was treated with few drops of acetic anhydride, boiled and 
cooled. Concentrated sulphuric acid was added from the side of the test tube, 
brown ring was formed at the junction of two layers and upper layer turned 
green which showed the presence of steroids and formation of deep red colour 
indicating the presence of triterpenoids. 
2. Salkowski Test 
The extract was treated with few drops of concentrated sulphuric acid, red 
colour formed at lower layer indicated the presence of steroids and formation 
of yellow coloured lower layer indicating the presence of triterpenoids.  
3. Hesses reaction 
The residue dissolved in chloroform and an equal quantity of concentrated 
sulphuric acid was then added along the side of the tube and observed for the 
formation of pink coloured ring, which on shaking diffused in both the layers. 
4. Hersch’s Sohn’s reaction 
 To the residue 2-3 ml of trichloroacetic acid was added, heated and 
observed for the formation of red to violet colour. 
 Test for Gums and Mucilage 
Small quantity of the extract was added separately to 25ml of absolute alcohol 
with constant stirring and filtered. No precipitate was formed, it indicates that 
absence of gums and mucilage. 
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6.3 ACUTE TOXICITY STUDY108 
 Whenever an investigator administers a chemical substance to a biological 
system, different types of interactions can occur and a series of dose-related responses 
result. In most cases these responses are desired and useful, but there are a number of 
other effects which are not advantageous. These may or may not be harmful to the 
patients. The types of toxicity tests which are routinely performed by pharmaceutical 
manufacturers in the investigation of new drug involve acute, sub-acute and chronic 
toxicity. Acute toxicity is involved in estimation of LD50 (the dose has proved to be lethal 
(causing death) to 50% of the tested group of animals). 
Determination of oral toxicity is usually an initial screening step in the 
assessment and the evaluation of the toxic characteristics of all compounds. This article 
reviews the methods of so far utilized for the determination of median lethal dose 
(LD50) and the new changes which would be made. This has to go through the entire 
process of validation with different categories of substances before its final acceptance 
by regulatory bodies. 
Organisation for Economic co-operation and Development (OECD) regulates 
guidelines for oral acute toxicity study. It is an international organisation which works 
with the aim of reducing both the number of animals and the level of pain associated 
with acute toxicity testing. To determine the acute oral toxicity OECD frames the 
following guideline methods. 
 OECD 401 – Acute Oral Toxicity 
 OECD 420 – Acute Oral Toxicity: Fixed Dose procedure 
 OECD 423 –Acute Oral Toxicity: Acute Toxic Classic method 
 OECD 425 – Acute Oral Toxicity: Up and own Procedure 
In the present study the acute oral toxicity of Mallotus Philippensis Muell.Arg. 
was carried out according to OECD 423 guideline (Acute Oral Toxicity: acute Toxic 
Classic Method). 
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ACUTE ORAL TOXICITY 
 Acute oral toxicity refers to those adverse effects that occur following oral 
administration of a single dose of a substance or multiple doses given within 24 hours. 
LD50 (median lethal oral dose) 
LD50 (median lethal oral dose) is a statistically derived single dose of a substance 
that can be expected to cause death in 50 per cent of animals when administered by the 
oral route. The LD50 value is expressed in terms of weight of test substance per unit 
weight of test animal (mg/kg). 
PRINCIPLE 
It is based on a stepwise procedure with the use of a minimum number of 
animals per step; sufficient information is obtained on the acute toxicity of the test 
substance to enable its classification. The substance is administered orally to a group of 
experimental animals at one of the defined doses. The substance is tested using a step 
wise procedure, each step using three animals of a single sex (normally females). 
Absence or presence of compound- related mortality of the animals dosed at one step 
will determine the next step, i.e. 
 No further testing is needed 
 Dosing of three additional animals, with the same dose 
 Dosing of three additional animals at the next higher or the next lower 
dose level. 
SELECTION OF ANIMAL SPECIES 
 The preferred rodent species was the rat. Normally females were used. 
Females were generally slightly more sensitive. Healthy young adult animals of 
commonly used laboratory strains were employed. Females were nulliparous and non-
pregnant. Each animal, at the commencement of it’s dosing, were between 8 to 12 
weeks old. 
ADMINISTRATION OF DOSES 
 The test substance was administered in a single dose by gavages using a 
oral feeding needle. Animals were fasted prior to dosing (e.g. with the rat, food but not 
water should be withheld over-night, with the mouse, food but not water was withheld 
for 3-4 hours). Following the period of fasting, the animals were weighed and the test 
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substance administered. After the substance has been administered, food was withheld 
for a further 3-4 hours in rats. 
OBSERVATION 
 Animals were observed individually after dosing at least once during the 
first 30 minutes, periodically during the first 24 hours, with special attention given during 
the first 4 hours, and daily thereafter, for a total of 21 days, except where they need to 
be removed from the study and humanely killed for animal welfare reasons or are found 
dead. However, the duration of observation was not fixed rigidly. It was determined by 
the toxic reactions, time of onset and length of recovery period and extended when 
considered necessary. The times at which signs of toxicity appeared and disappeared 
were important, when toxic signs were to be delayed. All observations were 
systematically recorded with individual records being maintained for each animal. 
 
6.4 PHARMACOLOGICAL SCREENING 
ANIMALS  
 Adult Wistar albino rats of either sex weighing 150-160 gm were  procured from 
the animal house of Kings institute, guindy, Chennai, Tamilnadu, India. used. The 
animals were maintained on the suitable nutritional and environmental condition 
throughout the experiment. 
 The animals were housed in polypropylene cages with paddy house bedding 
under standard laboratory conditions for an acclimatization periods of 7 days prior to 
performing the experiment. The animals had access to laboratory chow ad libitum 
(H.G.Vogel, 2002). 
The Institutional Animal Ethics Committee approved the experimental protocol 
and the conditions in the animal house approved by Committee for Supervision on 
Experiments on Animals. The study was conducted in accordance with IAEC guidelines 
(IAEC approval No: IAEC/XLVIII/04/CLBMCP/2016 dated on 04/05/2016).   
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6.4.1 STERPTOZOTOCIN INDUCED DIABETES59 
Experimental induction of diabetes  
  A freshly prepared solution of STZ (45 mg/kg in 0.1 M citrate buffer, pH 
4.5) was injected intraperitoneally to overnight-fasted rats The rats exhibited 
hyperglycaemia within 48 h of STZ administration. The rats having fasting blood glucose 
(FBG) values of 250 mg/dl or above were considered for the study. 
6.4.2 EXPERIMENTAL DESIGN 
The anti diabetic activity was tested on a total of 30 rats (24 diabetic rats and 6 normal 
rats) and they were divided into five groups and each group consists of 6 animals as 
follows, 
Group I- Served as control, received 0.5% CMC (1ml/kg; p.o) for 21 days. 
Group II- Diabetic control received single streptozocin injection (45mg/kg; b.wt; i.p) 
freshly prepared in citrate buffer on Day 1  and received citrate buffer for 21 days. 
Group III- STZ+ plant extract low dose (200mg/kg, b.wt; p.o) suspended in 0.5% CMC 
for 21days 
Group IV- STZ+ plant extract high dose (400mg/kg, b.wt; p.o) suspended in 0.5% CMC 
for 21days 
Group V- STZ+ Standard Glibenclamide (600 µg/kg, b.wt; p.o) dissolved in 5% CMC for 
21days 
6.4.3 DIABETIC STUDY 
 The study involved repeated administration of EEMP for 21 days at a prefixed 
times and blood glucose levels were estimated in samples withdrawn after 1st day, 7, 14 
and 21st day. The animals had free access to food and water during this period. 
 Blood samples from the experimental rats were collected from the tail by using 
pricking lancet. The collected blood samples were analyzed for blood glucose levels by 
the glucometer using strip technique and blood glucose levels were expressed in mg/dl. 
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BLOOD SAMPLE AND ORGANS COLLECTION 
 Fasting blood glucose of all rats was determined before the start of the 
experiment. On day 21st the blood was collected by retro orbital under mild ether 
anaesthesia from overnight fasted rats, into tubes containing potassium oxalate and 
sodium fluoride as anticoagulant for estimation of fasting plasma glucose. Plasma and 
serum were separated by centrifugation. After centrifugation at 2,000 rpm for 10 
minutes, the clear supernatant was used for the analysis of various biochemical 
parameters. After collection of blood, all the treated animals were sacrificed the 
pancreas and liver tissues were isolated and rinsed in ice- cold saline and kept in 
formalin solution (10%) for further histopathological studies. 
PREPARATION OF LIVER HOMOGENATE 
          The liver was quickly removed and perfused immediately with ice-cold saline 
(0.9% NaCl). A portion of the kidney was homogenized in chilled Tris-HCl buffer (0.025 
M, pH 7.4) using a homogenizer. The homogenate obtained was centrifuged at 5000 
rpm for 10 min, supernatant was collected and used for various biochemical assays. 
6.5 EVALUATION OF PARAMETERS 
Biochemical Estimation 
6.5.1 Estimation of blood glucose level 109 
The Blood glucose levels were estimated by Hexokinase method. Glucose is 
phosphorylated by hexokinase (HK) in the presence of adenosine triphosphate (ATP) 
and magnesium ions to produce glucose-6- phosphate and adenosine diphosphate 
(ADP). Glucose-6-phosphate dehydrogenase (G6P-DH) specifically oxidises glucose-6-
phosphate to gluconate-6-phosphate with the concurrent reduction of NAD+ to NADH. 
The increase in absorbance at 340nm is proportional to the glucose concentration in the 
sample.  
 
 
 
                                   HK, Mg2+   
 Glucose + ATP                                    Glucose-6-phosphate + ADP 
 
Glucose-6-Phosphate + NAD+                                                  Gluconate-6-P + NADH + H+  
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Reagents 
Reagent 1 
 0.05 M Tris HCl buffer, pH 8.0 with 13.3 mM MgCl2 
 0.67 M Glucose in Tris-MgCl2 buffer 
 16.5 mM ATP in Tris-MgCl2 buffer 
 6.8 mM NAD in Tris-MgCl2 buffer 
Reagent 1A 
 300 IU/ml Glucose-6-phosphate dehydrogenase in Tris-MgCl2 buffer 
 300 IU/ml Hexokinase in Tris-MgCl2 buffer 
Procedure 
        150 μl of reagent 1 was added with 30 μl of reagent 1A and to this 20 μl of suitable 
diluents was added and the contents were mixed thoroughly. To this mixture, 2 μl of 
serum sample was added. Then the contents were mixed and incubated at 37°C for 10 
seconds. After zeroing the instrument with blank the absorbance of standard followed 
by the test sample was measured at 340 nm. The values were expressed as mg/dl. 
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6.5.1.1 Estimation of Glycosylated Haemoglobin (HbA1C)110  
Method: “Tina-quant” (turbidimetric inhibition immunoassay”  
The  concentration  A1c  (HbA1c)  is  measured  as  a  percentage  of  a  total 
hemoglobin  in  human  whole blood (%HbA1c). Consequently, the hemoglobin 
contained in red  blood cells is  released  by  hemolysis  of  the  sample.  This  method  
uses the  Hemolyzing  Reagent  containing  a  detergent  (tetradecyltrimethylammonium  
bromide  -  TTAB)  to  specifically  lysate  red  blood  cells.  HbA1c and  Hemoglobin  
levels  in  the  sample  are  determined  from  the  obtained  hemolysate  by  two  
independent  reactions.  HbA1c  During  the  first  stage of  the  reaction:  the  HbA1c  in  
the  sample  reacts  with  the  anti-HbA1c  specific  antibody  (Reagent  A1)  to  form  
soluble  antigen-antibody complexes. Then the polyhapten is added (Reagent A2). The 
polyhapten reacts with the specific  antibody  excess  from  the  first  reaction,  
producing  insoluble  immune  complexes  which  can  be  measured turbidimetrically at 
340 nm.  
Reagents  
Reagent A1:  Monospecific antibodies anti-HbA1c in pH 6.2 buffer.  
Reagent A2:  Polyhapten-HbA1c in pH 6.2 buffer.  
Calculation  
%HbA1c = 91.5 x  HbA1c (g/dl) / Hb( gm/dl)  + 2.15 
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6.5.2 Estimation of serum parameters 
6.5.2.1 Estimation of total cholesterol level111 
Method-cholesterol oxidize- Peroxidase method. 
Principle 
 Cholesterol esterase hydrolyses cholesterol esters into free cholesterol and fatty 
acids. In the second reaction cholesterol oxidase converts cholesterol to cholest- 4-en-
3-one and hydrogen peroxide. In presence of peroxidase, hydrogen peroxide oxidatively 
couples with 4-aminoantipyrine and phenol to produce red quinoeimine dye which has 
absorbance maximum at 510 nm. The intensity of the red colour is proportional  to the 
amount of total cholesterol in the specimen  
                               Cholesterol esterase 
cholesterol esters             cholesterol + fatty acids 
cholesterol oxidase 
cholesterol + O2                                          H2O2 + cholest-4-en-3-one 
                                            peroxidase 
2H2O2 + 4-aminoantipyrine                               red quinoneimine +H2O + phenol 
 
 
Reagents 
 50 mMol/L Buffer, pH 6.8 
 Cholesterol oxidase 
 Cholesterol esterase 
 Peroxidase 
 0.mMol/L 4-amino antipyrine 
 Phenol 
 Surfactant 
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Assay parameters 
Reaction type -end point 
Reaction time -5 minutes at 37°C/ 10 minutes at 25°-30°C 
Wave length -510nm 
Procedure 
Sample-Serum 
The required amount of reagent before use was prewarmed at room temperature, the 
assay was performed as given below 
 Serum Standard Blank 
 10 µL 10 µL - 
Reagent 1000 µL 1000 µL 1000 µL 
 
Incubation 
 The assay mixture was incubated for 5 minutes at37°C , for 10 minutes at room 
temperature (25°-30°C). 
 After incubation the absorbance of the assay mixture was measured against 
blank at 510 nm. The final colour was stable for two hours if not exposed to direct light. 
Calculation 
 Total cholesterol (mg/dL)= (absorbance of test/absorbance of standard) X 200. 
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6.5.2.2 Estimation of Aspartate aminotransferase (AST, Serum Glutamic-
Oxaloacetic Transaminase)112 
          The enzyme catalyzes the reaction, 
                      
 
The enzyme activity was assayed by the method of Reitman and Frankel. 
Reagents: 
 Substrate: 1.33 g of L-aspartic acid and 15 mg of 2-oxo glutaric acid were 
dissolved in 20.5 ml of buffer and 1 N sodium hydroxide to adjust the pH to 7.4 
and made up to 100 ml with the phosphate buffer. 
 0.1N Sodium hydroxide 
 2,4-dinitro phenyl hydrazine (DNPH) (0.2% in 1 N HCl). 
 Standard pyruvate solution: 11 mg of sodium pyruvate was dissolved in 100 ml of 
phosphate buffer. This contains 1 μmole of pyruvate/ml 
Procedure: 
            1 ml of buffered substrate was incubated at 37°C for 10 minutes. Then 0.2 ml of 
serum /tissue homogenate was added in the test tubes and incubated at 37°C for 30 
minutes. The reaction was arrested by adding 1 ml of DNPH reagent and tubes were 
kept at room temperature for 20 minutes. Then 10 ml of 0.4N sodium hydroxide solution 
was added. A set of pyruvic acid was also treated in a similar manner for the standard. 
The colour developed was read at 520 nm against the reagent blank. The activity of the 
enzyme was expressed as IU/L / μmoles of pyruvate liberated/min/mg protein. 
      L-aspartate + 2-oxoglutarate → oxaloacetate + L-gluatamate 
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6.5.2.3 Estimation of Alanine aminotransferase (ALT, Serum Glutamic-Pyruvic 
Transaminase)113. 
This enzyme c0atalyzes the reaction, 
 
 
The enzyme activity was assayed by the method of Reitman and Frankel. 
Reagents: 
 Phosphate buffer: 0.1 M; pH 7.4. 
 Substrate: 1.78 g of DL-alanine and 30 mg of 2-oxo glutaric acid were dissolved 
in 20 ml of buffer. About 0.5 ml of 1 N sodium hydroxide was added and made up 
to 100 ml with buffer. 
 0.1N Sodium hydroxide. 
 2, 4-dinitro phenyl hydrazine (DNPH): 0.2% in 1 N HCl. 
 Standard pyruvate solution: 11 mg of sodium pyruvate was dissolved in 100 ml of 
phosphate buffer. This contained 1 μmole of pyruvate/ml. 
Procedure: 
            1 ml of buffered substrate was incubated at 37°C for 10 minutes. Then 0.2ml of 
serum/tissue homogenate was added in the test tubes and incubated at37°C for 30 
minutes. The reaction was arrested by adding 1 ml of DNPH reagent and tubes were 
kept at room temperature for 20 minutes. Then 10 ml of 0.4N sodium hydroxide solution 
was added. A set of pyruvic acid was also treated in a similar manner for the standard. 
The colour developed was read at 520 nm against the reagent blank. The activity of the 
enzyme was expressed as IU/L / μmoles of pyruvate liberated/min/mg protein. 
      L-alanine + 2-oxoglutarate → oxaloacetate + L-gluatamate 
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6.5.3 Estimation of oxidative stress parameters 
6.5.3.1 Estimation of Lipid Peroxidation (LPO)114 
            Lipid peroxidation (LPO) was assayed by the method of Ohkawa et al, in which 
the malondialdehyde (MDA) released served as the index of LPO. The extent of LPO in 
the hepatic tissue was assayed by measuring one of the end products of this process, 
the thiobarbituric acid-reactive substances (TBARS). As 99% TBARS is 
malondialdehyde (MDA), thus this assay is based on the reaction of 1 molecule of MDA 
with 2 molecules of TBARS at low pH (2- 3) and at a temperature of 95°C for 60 min. 
The resultant pink chromogen can be detected spectrophonometrically at 532 nm. 
Reagents 
 Standard: 1, 1, 3, 3-tetra ethoxypropane (TEP). 
 8.1% Sodium dodecyl sulphate (SDS) 
 20%Acetic acid 
 0.8%Thiobarbituric acid (TBA)  
 15:1 v/v n-butanol: pyridine mixture 
Procedure 
           To 0.2 ml of tissue homogenate, 0.2 ml of 8.1% SDS, 1.5 ml of 20% acetic acid 
(pH 3.5) and 1.5 ml of 0.8% TBA were added. The mixture was made up to 4 ml with 
water and then heated in a water bath at 95.8ºC for 60 min using glass ball as a 
condenser. After cooling, 1 ml of water and 5 ml of n-butanol: pyridine (15:1 v/v) mixture 
were added and shaken vigorously. After centrifugation at 4000 rpm for 10 min, the 
organic layer was taken and its absorbance was measured at 532 nm. The level of lipid 
peroxides was expressed as nmoles of MDA formed/mg of protein. 
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6.5.4 Evaluation of Enzymic Hepatic Antioxidants 
6.5.4.1 Estimation Superoxide dismutase (SOD)115 
         This enzyme catalyzes the dismutation of superoxide anion (O2-.) to hydrogen 
peroxide and molecular oxygen in the following manner 
 
 
 
The enzyme activity was assayed by the method of Misra and Fridovich. 
Reagents 
  0.1 M Carbonate-bicarbonate buffer; pH 10.2. 
 0.6 mM EDTA solution 
 1.8 mM Epinephrine (prepared in situ) 
  Absolute ethanol. 
  Chloroform 
Procedure 
        0.1 ml of tissue homogenate was added to the tubes containing 0.75 ml ethanol 
and 0.15 ml chloroform (chilled in ice) and centrifuged. To 0.5 ml of supernatant, added 
0.5 ml of 0.6 mM EDTA solution and 1 ml of 0.1 M carbonate-bicarbonate (pH 10.2) 
buffer. The reaction was initiated by the addition of 0.5 ml of 1.8 mM epinephrine 
(freshly prepared) and the increase in absorbance at 480 nm was measured. One unit 
of the SOD activity was the amount of protein required to give 50% inhibition of 
epinephrine autoxidation. 
                 H2O + 2O2-. + 2H+ → 2H2O2 + O2 
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6.5.4.2 Estimation of Catalase (CAT)116 
                This enzyme catalyzes conversion of hydrogen peroxide into water and 
molecular oxygen. 
 
  
The enzyme activity was assayed by the method of Sinha  .  
 
Reagents 
 Dichromate-acetic acid reagent: 5% potassium dichromate in water was mixed 
with glacial acetic acid in the ratio of 1:3 (v/v). 
 0.01 M Phosphate buffer; pH 7.0. 
 0.2M Hydrogen peroxide 
Procedure 
             0.1 ml of the tissue homogenate was added to the reaction mixture containing 
1ml of 0.01 M phosphate buffer (pH 7.0) pre-warmed to 37°C, 0.4 ml of distilled water 
and the mixture was incubated at 37°C. The reaction was initiated by the addition of 0.5 
ml of 0.2 M hydrogen peroxide and the reaction mixture was incubated at 37°C for one 
minute. The reaction was terminated by the addition of 2 ml of dichromate-acetic acid 
reagent after 15, 30, 45, and 60 seconds. Standard hydrogen peroxide in the range of 
4-20 μmoles were taken and treated in the same manner. All the tubes were heated in a 
boiling water bath for 10 minutes, cooled and the green colour that developed was read 
at 590 nm against blank containing all components except the enzyme. Catalase activity 
was expressed in terms of μmoles of H2O2 consumed/min/mg protein. 
                     2H2O2 → 2H2O + O2 
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6.5.4.3 Estimation of Glutathione peroxidase (GPx)117 
This enzyme catalyzes the reduction of H2O2 using glutathione as substrate. 
 
  
 
The enzyme activity was assayed by the method of Rotruck et al. 
 
Reagents 
 0.32 M Sodium phosphate buffer; pH 7.0. 
 0.8 mM EDTA 
 10 mM Sodium azide. 
 4mM Reduced glutathione. 
 2.5 mM Hydrogen peroxide. 
 10%Trichloro acetic acid (TCA). 
 0.3M Disodium hydrogen phosphate. 
 0.04% 5,5'-dithiobis (2-nitro benzoic acid) (DTNB); 40 mg of DTNB in 1% sodium 
citrate. 
 10 mM Standard reduced glutathione. 
Procedure 
             The assay mixture containing 0.5 ml sodium phosphate buffer, 0.1 ml of 10mM 
sodium azide, 0.2 ml of 4 mM reduced glutathione, 0.1 ml of 2.5 mM H2O2, and 0.5 ml of 
1:10 tissue homogenate was taken and the total volume was made up to 2.0 ml with 
distilled water. The tubes were incubated at 37 8C for 3 min and the reaction was 
terminated by the addition of 0.5 ml of 10% TCA. To determine the residual glutathione 
2GSH + H2O2 → GSSG + 2H2O 
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content, the supernatant was removed after centrifugation, and to this 4.0 ml disodium 
hydrogen phosphate (0.3 M) solution and 1 ml DTNB reagent were added. The colour 
that developed was read at 412 nm against a reagent blank containing only phosphate 
solution and DTNB reagent in a spectrophotometer. Suitable aliquots of the standard 
were also treated similarly. The enzyme activity is expressed in terms of μg of GSH 
utilized/min/mg protein. 
6.5.5 Evaluation of Non-Enzymic Hepatic Antioxidants 
6.5.5.1 Estimation of Reduced glutathione (GSH)118 
             The total reduced glutathione was determined according to the method of 
Ellman. The assay procedure is based on the reduction of Ellman´s reagent [5, 5΄- dithio 
bis (2- nitrobenzoic acid)] (DTNB) by SH groups of glutathione to form 2-nitro-S-
mercaptobenzoic acid per mole of glutathione. The product is measured 
spectrophotometically at 412 nm. 
 
Reagents 
 0.2 M Phosphate buffer; pH 8.0. 
 0.6 mM DTNB reagent. 
 5%TCA  
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Procedure 
              0.1 ml of tissue homogenate was precipitated with 5% TCA. The contents were 
mixed well for complete precipitation of proteins and centrifuged. To 0.1 ml of 
supernatant, 2 ml of 0.6 mM DTNB reagent and 0.2 M phosphate buffer (pH 8.0) were 
added to make up to a final volume of 4 ml. The absorbance was read at 412 nm 
against a blank containing TCA instead of sample. A series of standards treated in a 
similar way also run to determine the glutathione content. The amount of glutathione 
was expressed as nmoles/g tissue. 
6.5.5.2 Estimation of Vitamin C (Ascorbic acid)119 
           The level of vitamin C was estimated by the method of Omaye et al. Ascorbic 
acid is oxidised by copper to form dehydroascorbic acid. The product was treated with 
2,4 dinitrophenyl hydrazine to form tris 2,4 dinitrophenyl hydrazone which undergoes 
rearrangement to form a product with the absorption maximum at 520 nm in 
spectrophotometer. 
Reagents 
 5% TCA 
 DTC reagent (3 gm of 2,4 dinitrophenyl hydrazine, 0.4 gm thiourea and 0.05 gm 
of copper sulphate were dissolved in 100 ml of 9 N H2SO4). 
 65 % H2SO4 (ice cold) 
 Standard ascorbic acid 
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Procedure 
             To 0.5 ml of tissue homogenate, 0.5 ml of water and 1 ml of TCA were added, 
mixed thoroughly and centrifuged. To 1 ml of the supernatant, 0.2 ml of DTC reagent 
was added and incubated at 37°C for 3 hours. Then 1.5 ml of H2SO4 was added, mixed 
well and the solution was allowed to stand for 30 minutes at room temperature. The 
colour developed was read at 520 nm in spectrophotometer. The level of vitamin C was 
expressed as nmole/ g of wet tissue. 
6.5.5.3 Estimation of Vitamin E (α- Tocopherol)120 
           Vitamin E content was estimated by the method of Palan et al. This method 
involves the conversion of ferric ions to ferrous ions by a-tocopherol and the formation 
of red colored complex with 2, 2 dipyridyl. Absorbance of chromophore was measured 
at 520 nm in the spectrophotometer. 
Reagents 
 2% 2,2 dipyridyl solution 
 5 % FeCl3 solution 
 Standard : 100 mg of α-tocopherol in 0.1% ethanol 
 n- Butanol 
Procedure 
             To 0.5 ml of tissue homogenate, 1.5 ml of ethanol was added, mixed and 
centrifuged. The supernatant was dried at 80°C for 3 hours. To this 0.2 ml of 2, 2 
dipyridyl solution and 0.2 ml of FeCl3 solution were added, mixed well and 4 ml of 
butanol was added. The colour developed was read at 520 nm in the 
spectrophotometer. The level of vitamin C was expressed as nmole/ g of wet tissue. 
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6.5.6 ESTIMATION OF PLASMA INSULIN LEVEL121 
 Insulin was assayed in plasma using a commercial kit by enzyme linked 
immunosorbant assay (ELISA) technique. 
Reagents used for the estimation of plasma insulin level: 
1. Monoclonal anti-insulin antibody 
2. Enzyme conjugate: Anti-insulin antibodies conjugated to horseradish 
peroxidise 
3. Standard: Human insulin 
4. Solution A: Buffer solution containing hydrogen peroxide  
5. Solution B: Tetramethylbenzidine 
6. Concentrated wash buffer 
7. Stock solution: 2 N HCL 
Procedure: 
 25 µl of the plasma taken into micro wells coated with anti-insulin antibody. To 
this, 100µl of the enzyme conjugate was added to each well, mixed for 5 sec and 
incubated at 25°C for 30 min. The wells were rinsed for five times with washing buffer. 
Then, 100µl of solution A and then 100µl of solution B were added to each well. This 
was incubated for 15 min at room temperature. The reaction was stopped by the 
addition of 50µl of 2 N HCL to each well and read at 450 nm.  
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6.7 HISTOPATHOLOGICAL STUDIES113  
           Hematoxylin, a basic bye is oxidized to hematein with a mordant, a metallic ion 
such as the salts of aluminium. The positively charged aluminium-hematein complex 
combines with the negatively charged phosphate groups of the nucleic acids (DNA and 
RNA) forming blue/purple colour, which is characteristic of hematoxylin stains. Eosin is 
an acidic dye, which is considered to have a selective affinity for the basic parts of the 
cell, i.e., the cytoplasm. Thus, the hematoxylin and eosin (H & E) stain is used to 
demonstrate different structures of the tissue. 
             The various steps involved in the preparation of pancreatic tissues for 
histological studies are as follows: 
 Fixation 
                        In order to avoid tissue by the lysosomal enzymes and to preserve its 
physical and chemical structure, a bit of tissue from each organ was cut and fixed in 
bouin’s fluid immediately after removal from the animal body. The tissues were fixed in 
bouin’s fluid for about 24 hours. The tissues were then taken and washed in glass 
distilled water for a day to remove excess of picric acid. 
 Dehydration 
                        The tissues were kept in the following solutions for an hour each; 30%, 
50%, 70% and 100% alcohol. Inadequately dehydrated tissues cannot be satisfactorily 
infiltered with paraffin. At the same time over dehydration results in making the tissues 
brittle, which would be difficult for sectioning. So, careful precautions were followed 
while performing the dehydration process 
 Clearing 
                        Dealcoholization or replacement of alcohol from the tissues with a 
clearing agent is called as clearing. Xylene was used as the clearing agent for one or 
two hours, two or three times. Since, the clearing agent is miscible with both 
dehydration and embedding agents, it permits paraffin to infilterate the tissues. So, the 
clearing was carried out as the next step after dehydration to permit tissue spaces to be 
filled with paraffin. The tissues were kept in the clearing agent till they become 
transparent and impregnated with xylene. 
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 Impregnation 
                         In this process the clearing agent xylene was placed by paraffin wax. 
The tissues were taken out of xylene and were kept in molten paraffin embedding bath, 
which consists of metal pots filled with molten wax maintained at about 50oC. The 
tissues were given three changes in the molten wax at half an hour intervals. 
 Embedding 
                      The paraffin wax used for embedding was fresh and heated upto the 
optimum melting point at about 56–58oC. A clear glass plate was smeared with 
glycerine. L-shaped mould was placed on it to from a rectangular cavity. The molten 
paraffin wax was poured and air bubbles were removed by using a hot needle. The 
tissue was placed in the paraffin and oriented with the surface to be sectioned. Then the 
tissue was pressed gently towards the glass plate to make settle uniformly with a metal 
pressing rod and allowed the wax to settle and solidity room temperature. The paraffin 
block was kept in cold water for cooling. 
 Section Cutting 
                       Section cutting was done with a rotatory microtome. The excess of 
paraffin around the tissue was removed by trimming, leaving ½ cm around the tissue. 
Then the block was attached to the gently heated holder. Additional support was given 
by some extra wax, which was applied along the sides of the block. Before sectioning, 
all set screws holding the object holder and knife were hand tightened to avoid vibration. 
To produce uniform sections, the microtome knife was adjusted to the proper angle in 
the knife holder with only the cutting edge coming in contact with the paraffin block. The 
tissue was cut in the thickness range of about 7µm. 
 Flattening and Mounting of Sections 
                        The procedure was carried out in tissue flotation warm water bath. The 
sections were spread on a warm water bath after they were detached from the knife 
with the help of hair brush. Dust free clean slides were coated with egg albumin over the 
whole surface. Required sections were spread on clean slide and kept at room 
temperature 
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 Staining of Tissue Sections 
                       The sections were stained as follows; deparaffinization with xylene two 
times 
each for five minutes 
Dehydration through descending grades of ethyl alcohol 
 100% alcohol (absolute) - 2 minute 
 90% alcohol - 1minute 
 50% alcohol - 1 minute 
Staining with Ehrlich’s Haemaoxylin was done for 15-20 minutes. Then the sectioned 
tissues were thoroughly washed in tap water for 10 minutes. Rinsed with distilled water 
and stained with Eosin. Dehydration again with ascending grades of alcohol. 
 70% alcohol - 2 minute 
 90% alcohol - 2 minute 
 100%alcohol - 1 minute 
Finally the tissues were cleared with xylene two times, each for about 3 minutes 
interval. 
 Mounting 
                        On the stained slide, DPX mountant was applied uniformly and micro 
glass cover slides were spread. The slides were observed in Nikon microscope and 
microphotographs were taken. 
 
STATISTICAL ANALYSIS 
The data of all the results were represented as Mean ± S.E.M. on statistically 
analysed by one-way ANOVA followed by Tukey’s multiple comparison test was used 
for statistical analysis p<0.05 was considered significant. 
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7. RESULTS 
7.1 Appearance and percentage yield of EEMP 
     Table no: 4 
Drug Mallotus Philippensis Muell.Arg. 
Solvent Ethanol 
Colour Brownish 
Consistency Semi solid 
Percentage yield 21.41 % w/w 
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7.2 PRELIMINARY PHYTOCHEMICAL SCREENING 
Table no-5:  Results of the Preliminary Phytochemical Constituents present in ethanolic 
extract of Mallotus philippensis Muell.Arg.  
Table no: 5 Preliminary phytochemical constituents present in EEMP 
S. 
No Constituents 
Mallotus 
philippensis 
Ethanolic extract 
1. Alkaloids _ 
2. Carbohydrates + 
3. Protein + 
4. Steroids + 
5. Phenols + 
6. Tannins + 
7. Flavanoids + 
8. 
Gums and 
Mucilage 
_ 
9. Glycosides + 
10. Sterols _ 
11. Saponins _ 
12. Terpenes + 
 
+ve Indicates the presence  -ve Indicates the absence 
RESULTS: The phytochemical constituents present in the ethanolic extract of Mallotus 
philippensis Muell.Arg.  were carbohydrates, steroids, phenols, tannins, flavanoids,  
glycosides, proteins and terpenes. 
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7.3 Estimation of Blood glucose level 
The effect of the different doses of ethanolic extract of Mallotus philippensis Muell.Arg. 
on blood glucose level 
Table no 6: Results of the effect of EEMP on blood glucose level  
 
The values were expressed as Mean ± S.E.M. (n=6 animals in each group).  
*= when compared to the control group. 
** = when compared to the STZ treated group. 
NS-Non significant. 
Data was analysed by one-way ANOVA followed by Tukey’s multiple comparison test. 
Blood Glucose level (mg/dl) 
Treatment  0 day 7th day 14th day 21st day 
Control 0.5% 
CMC (1ml/kg; p.o) 
85.12± 1.87 86.12 ± 2.12 86.54±1.92 87.12±1.24 
STZ  
(45mg/kg; b.wt; i.p) 
271.76 ± 4.90 280.45±3.87* 288.78±4.32 * 296.56±4.87 * 
STZ + Plant extract 
LD 
(200mg/kg, b.wt; 
p.o)  
276.56±3.65 
NS 
170.78±2.98** 158.87±3.12 
** 
153.87±2.87** 
STZ+ Plant extract 
HD 
(400mg/kg, b.wt; 
p.o) 
274.64 ± 3.8NS 150.65±3.72** 135.82±2.12  
** 
105.32±1.76 
** 
STZ+ Glibenclamide  
(600 µg/kg, b.wt; 
p.o) 
272.24 ± 4.65 
NS 
104.25±2.34** 98.98±1.65 ** 89.21±0.87 ** 
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Fig.no-7: Diagrammatic representation of the results of the effects of EEMP 
on blood glucose levels 
RESULTS 
The blood glucose levels were measured in 0 day, 7th day,14thst day and 21st day 
as showed in Table no-6 and Fig. no-7. 
The diabetic treated (Group 2) on 0 day, 7th day,14thst day and 21st day showed 
significant increase in blood glucose levels (hyperglycemia) when compared to the 
normal control (Group 1). Standard (Group 5) in 7thday, 14th day and 21st day showed 
statistically significant decrease in blood glucose level when compared to diabetic 
control (Group2). EEMP (200 mg/kg) treated (Group 3) showed statistically significant 
decrease in blood glucose level in 21st day when compared to the diabetic control 
(Group 2). EEMP (400mg/kg) treated (Group 4) showed statistically significant decrease 
in blood glucose level in 7th day,14th day and 21st day when compared to the diabetic 
control (Group 2).  
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7.4 Glycosylated haemoglobin level 
The effect of the different dose of Ethanolic extract of Mallotus philippensis Muell Arg  
on Glycosylated Haemoglobin level. 
Table no-7: Results of the effect of EEMP on Glycosylated haemoglobin  level 
 
 
 
 
 
 
 
 
 
 
The values were expressed as Mean ± S.E.M. (n=6 animals in each group).  
*= when compared to the control group. 
** = when compared to the STZ treated group. 
Data was analysed by one-way ANOVA followed by Tukey’s multiple comparison 
test. 
 
 
Groups HbA1c 
Control 0.5% 
CMC (1ml/kg; p.o) 
4.61±0.87 
STZ  
(45mg/kg; b.wt; i.p) 
8.95±0.76* 
STZ + Plant extract 
LD 
(200mg/kg, b.wt; p.o)  
6.12±0.65** 
STZ+ Plant extract 
HD 
(400mg/kg, b.wt; p.o) 
5.87±0.72** 
STZ+ Glibenclamide  
(600 µg/kg, b.wt; p.o) 
5.12±0.93** 
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  Fig. 
No-8: Diagrammatic representation of the results of the effects of EEMP on 
Glycosylated Haemoglobin level. 
RESULTS 
The Glycosylated Haemoglobin levels were measured were showed in Table no-
7 and Fig. no-8. 
The diabetic control (Group 2) showed significant increase in Glycosylated 
Haemoglobin level when compared to the normal control (Group1).  
Standard (Group 5) showed statistically significant decrease in Glycosylated 
Haemoglobin level when compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant decrease in 
Glycosylated Haemoglobin level when compared to the diabetic control (Group 2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant decrease in 
Glycosylated Haemoglobin level when compared to the diabetic control (Group 2). 
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7.5 ESTIMATION OF SERUM PARAMETERS 
7.5.1 Estimation of Total cholesterol level 
The effect of the different dose of Ethanolic extract of Mallotus philippensis Muell.Arg. 
on Total cholesterol level. 
Table no-8: Results of the effect of EEMP on Total cholesterol level 
Groups Total cholesterol 
level 
Control 0.5% 
CMC (1ml/kg; p.o) 
65.88±1.203 
STZ  
(45mg/kg; b.wt; i.p) 
140.38±1.244* 
STZ + Plant extract 
LD 
(200mg/kg, b.wt; p.o)  
77±2.399** 
STZ+ Plant extract 
HD 
(400mg/kg, b.wt; p.o) 
72.06±2.033** 
STZ+ Glibenclamide  
(600 µg/kg, b.wt; p.o) 
69.48±2.333** 
 
The values were expressed as Mean ± S.E.M. (n=6 animals in each group).  
*= when compared to the control group. 
** = when compared to the STZ treated group. 
Data was analysed by one-way ANOVA followed by Tukey’s multiple comparison 
test. 
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Fig. No-9: Diagrammatic representation of the results of the effects of EEMP on 
Total Cholesterol  level. 
RESULTS 
The Total Cholesterol  levels were measured were showed in Table no-8 and 
Fig. no-9. 
The diabetic control (Group 2) showed significant increase in Total Cholesterol  
level when compared to the normal control (Group1).  
Standard (Group 5) showed statistically significant decrease in Total Cholesterol  
level  when compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant decrease in 
Total Cholesterol  level when compared to the diabetic control (Group 2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant decrease in 
Total Cholesterol  level when compared to the diabetic control (Group 2). 
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7.5.2 Effect of plant extract on serum  aspartate aminotransferase (AST) level and              
serum alanine aminotransferase  (ALT) level 
 The effect of the different doses of Ethanolic extract of Mallotus 
philippensis Muell Arg on serum  aspartate aminotransferase (AST) level. 
 The effect of the different doses of Ethanolic extract of Mallotus 
philippensis Muell Arg on serum alanine aminotransferase (ALT) level. 
Table no 9: Results of the effect of EEMP on serum  aspartate aminotransferase 
(AST) level and serum alanine aminotransferase  (ALT) level 
Groups AST (IU/L) ALT(IU/L) 
Control 0.5% 
CMC (1ml/kg; p.o) 
52.25±4.26 49.16±3.76 
STZ  
(45mg/kg; b.wt; i.p) 
121.76±6.12* 95.76±5.18* 
STZ + Plant extract 
LD 
(200mg/kg, b.wt; p.o)  
67.98±3.86** 58.24±3.89** 
STZ+ Plant extract 
HD 
(400mg/kg, b.wt; p.o) 
60.56±3.78** 55.35±2.76** 
STZ+ Glibenclamide  
(600 µg/kg, b.wt; p.o) 
55.24±4.53** 52.68±3.92** 
The values were expressed as Mean ± S.E.M. (n=6 animals in each group).  
*= when compared to the control group. 
** = when compared to the STZ treated group. 
Data was analysed by one-way ANOVA followed by Tukey’s multiple comparison test. 
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Fig. No-10: Diagrammatic representation of the results of the effects of EEMP on 
Serum aspartate aminotransferase (AST) level and Serum alanine 
aminotransferase  (ALT) level. 
RESULTS 
 Serum  aspartate aminotransferase (AST) level 
The serum aspartate aminotransferase (AST) levels were measured were showed in 
Table no-9 and Fig. no-10. 
The diabetic control (Group 2) showed significant increase in serum aspartate 
aminotransferase (AST) level when compared to the normal control (Group 1).  
Standard (Group 5) showed statistically significant decrease in liver serum aspartate 
aminotransferase (AST) level when compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant decrease in serum 
aspartate aminotransferase (AST) level when compared to the diabetic control (Group 
2).  
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EEMP 400mg/kg treated (Group 4) showed statistically significant decrease in serum 
aspartate aminotransferase (AST) level when compared to the diabetic control (Group 
2). 
 Serum alanine aminotransferase  (ALT) level 
The serum alanine aminotransferase (ALT) levels were measured were showed in 
Table no-9 and Fig. no-10. 
The diabetic control (Group 2) showed significant increase in serum alanine 
aminotransferase (ALT) level when compared to the normal control (Group 1).  
Standard (Group 5) showed statistically significant decrease in serum alanine 
aminotransferase (ALT) level when compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant decrease in serum 
alanine aminotransferase (ALT) level when compared to the diabetic control (Group2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant decrease in serum 
alanine aminotransferase (ALT) level when compared to the diabetic control (Group 2). 
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7.6 ESTIMATION OF OXIDATIVE STRESS PARAMETERS 
7.6.1 Effect of EEMP on liver Malondialdehyde (MDA) level 
 The effect of the different dose of ethanolic extract of Mallotus philippensis Muell 
Arg  on Liver Malondialdehyde (MDA) level. 
Table no-10: Results of the effect of EEMP on MDA level 
Groups MDA 
Control 0.5% 
CMC (1ml/kg; p.o) 
1.78±0.06 
STZ  
(45mg/kg; b.wt; i.p) 
3.68±0.03 * 
STZ + Plant extract LD 
(200mg/kg, b.wt; p.o)  
2.43±0.03 ** 
STZ+ Plant extract HD 
(400mg/kg, b.wt; p.o) 
1.93±0.04 ** 
STZ+ Glibenclamide  
(600 µg/kg, b.wt; p.o) 
1.64±0.02  ** 
 
The values were expressed as Mean ± S.E.M. (n=6 animals in each group. 
*= when compared to the control group. 
** = when compared to the STZ treated group. 
Data was analysed by one-way ANOVA followed by Tukey’s multiple comparison test. 
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Fig. No-11: Diagrammatic representation of the results of the effects of EEMP on 
liver malondialdehyde (MDA) level. 
RESULTS 
The Liver malondialdehyde (MDA) levels were measured were showed in Table 
no-10 and Fig. no-11. 
The diabetic control (Group 2) showed significant increase in liver 
malondialdehyde (MDA) level when compared to the normal control (Group1).  
Standard (Group 5) showed statistically significant decrease in liver 
malondialdehyde (MDA) level when compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant decrease in 
liver malondialdehyde (MDA) level when compared to the diabetic control (Group 2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant decrease in 
liver malondialdehyde (MDA) level when compared to the diabetic control (Group 2). 
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7.7 ESTIMATION OF ANTIOXIDANT PARAMETERS  
7.7.1 Effect of EEMP on Enzymic hepatic antioxidant level (SOD, CAT and GPx.) 
 The effect of the different doses of Ethanolic extract of Mallotus 
philippensis Muell Arg on Liver superoxide dismutase (SOD) level. 
 The effect of the different doses of Ethanolic extract of Mallotus 
philippensis Muell Arg on Liver Catalase (CAT) level 
 The effect of the different doses of Ethanolic extract of Mallotus 
philippensis Muell Arg on glutathione peroxidase  (GPx) level 
Table no 11: Results of the effect of EEMP on enzymic hepatic 
antioxidant levels (SOD, CAT and GPx.) 
Groups SOD CAT GPx 
Control 0.5% 
CMC (1ml/kg; p.o) 
2.66±0.01 15.21±0.07 1.71±0.05 
STZ  
(45mg/kg; b.wt; i.p) 
0.45±0.02 * 2.76±0.04 * 0.36±0.02 * 
STZ + Plant extract LD 
(200mg/kg, b.wt; p.o)  
0.75±0.02** 6.76±0.03 b** 0.44±0.02 
NS 
STZ+ Plant extract HD 
(400mg/kg, b.wt; p.o) 
1.82±0.07 ** 12.62±0.11 
** 
1.14±0.02 ** 
STZ+ Glibenclamide  
(600 µg/kg, b.wt; p.o) 
2.13±0.02 ** 13.50±0.24 
** 
1.70±0.09 ** 
The values were expressed as Mean ± S.E.M. (n=6 animals in each group).  
*= when compared to the control group. 
** = when compared to the STZ treated group. 
NS-Non significant 
Data was analysed by one-way ANOVA followed by Tukey’s multiple comparison test. 
  RESULTS 
 
DEPARTMENT OF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE Page 107 
 
Data 1
S
O
D
C
A
T
G
P
x
0
5
10
15
20
normal control
diabetic control
test low dose (200mg/kg)
test high dose (400mg/kg)
reference control
e
n
z
y
m
ic
 a
n
ti
 o
x
id
a
n
t 
le
v
e
l
 Fig. No-12: Diagrammatic representation of the results of the effects of 
EEMP on Enzymic hepatic antioxidant levels (SOD, CAT and GPx.). 
RESULTS 
 Superoxide dismutase (SOD) levels 
The superoxide dismutase (SOD) levels were measured were showed in Table 
no-11 and Fig. no-12. 
The diabetic control (Group 2) showed significant decrease in liver superoxide 
dismutase (SOD) level when compared to the normal control (Group 1).  
Standard (Group 5) showed statistically significant increase in liver superoxide 
dismutase (SOD) level when compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant increase in 
liver superoxide dismutase (SOD) level when compared to the diabetic control (Group 
2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant increase in 
liver superoxide dismutase (SOD) level when compared to the diabetic control (Group 
2). 
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 Catalase (CAT) level 
The CAT levels were measured were showed in Table no-11 and Fig. no-12. 
The diabetic control (Group 2) showed significant decrease in liver catalase 
(CAT) level when compared to the normal control (Group 1).  
Standard (Group 5) showed statistically significant increase in liver catalase 
(CAT) level when compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant increase in 
liver catalase (CAT) level when compared to the diabetic control (Group 2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant increase in 
liver catalase (CAT) level when compared to the diabetic group. 
 Glutathione peroxidise (GPx) level 
The glutathione peroxidase  (GPx)  levels were measured were showed in Table 
no-11 and Fig. no-12. 
The diabetic control (Group 2) showed significant decrease in glutathione 
peroxidase (GPx)  level when compared to the normal control (Group 1).  
Standard (Group 5) showed statistically significant increase in glutathione 
peroxidase (GPx) level when compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant increase in 
glutathione peroxidise (GPx)  level when compared to the diabetic control (Group 2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant increase in 
glutathione peroxidise (GPx)  level when compared to the diabetic group. 
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7.7.2 Effect of EEMP on Non enzymic hepatic antioxidant level (GSH, Vit.C and 
Vit.E) 
 The effect of the different doses of Ethanolic extract of Mallotus 
philippensis Muell Arg on Reduced Glutathione (GSH) level. 
 The effect of the different doses of Ethanolic extract of Mallotus 
philippensis Muell Arg on Vit. C level 
 The effect of the different doses of Ethanolic extract of Mallotus 
philippensis Muell.Arg. on Vit.E level 
Table no 12: Results of the effect of EEMP on Non enzymic antioxidant 
levels (GSH, Vit.C and Vit.E) 
Groups GSH Vit.C Vit.E 
Control 0.5% 
CMC (1ml/kg; p.o) 
3.68±0.26 0.40 ±0.02 1.80±0.06 
STZ  
(45mg/kg; b.wt; i.p) 
1.26±0.09 * 0.18±0.02 * 0.76±0.07 * 
STZ + Plant extract 
LD 
(200mg/kg, b.wt; p.o)  
1.91±0.13 ** 0.26±0.03 
** 
1.45±0.08 
** 
STZ+ Plant extract 
HD 
(400mg/kg, b.wt; p.o) 
3.05±0.16 ** 0.32±0.04 
** 
1.69±0.09 
** 
STZ+ Glibenclamide  
(600 µg/kg, b.wt; p.o) 
2.57±0.12 ** 0.33±0.03 
** 
1.75±0.05 
** 
The values were expressed as Mean ± S.E.M. (n=6 animals in each group).  
*= when compared to the control group. 
** = when compared to the STZ treated group. 
Data was analysed by one-way ANOVA followed by Tukey’s multiple comparison test. 
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Fig. No-13: Diagrammatic representation of the results of the effects of EEMP on 
Non enzymic antioxidant level (GSH, Vit.C and Vit.E) 
RESULTS 
 Reduced Glutathione (GSH) level. 
The Reduced Glutathione (GSH) levels were measured were showed in Table 
no-12 and Fig. no-13. 
The diabetic control (Group 2) showed significant decrease in Reduced 
Glutathione (GSH) level when compared to the normal control (Group 1).  
Standard (Group 5) showed statistically significant increase in Reduced 
Glutathione (GSH) level when compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant increase in 
Reduced Glutathione (GSH) level when compared to the diabetic control (Group 2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant increase in 
Reduced Glutathione (GSH) level when compared to the diabetic control (Group 2). 
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 Vit.C level 
The Vit.C levels were measured were showed in Table no-12 and Fig. no-13. 
The diabetic control (Group 2) showed significant decrease in Vit.C level when 
compared to the normal control (Group 1).  
Standard (Group 5) showed statistically significant increase in Vit.C level when 
compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant increase in 
Vit.C level when compared to the diabetic control (Group 2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant increase in 
Vit.C level when compared to the diabetic group. 
 Vit.E level 
The Vit.E levels were measured were showed in Table no-12 and Fig. no-13. 
The diabetic control (Group 2) showed significant decrease in Vit.E level when 
compared to the normal control (Group 1).  
Standard (Group 5) showed statistically significant increase in Vit.E level when 
compared to diabetic control (Group 2). 
 EEMP 200 mg/kg treated (Group 3) showed statistically significant increase in 
Vit.E level when compared to the diabetic control (Group 2).  
EEMP 400mg/kg treated (Group 4) showed statistically significant increase in 
Vit.E level when compared to the diabetic group. 
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7.8 Effect of EEMP on plasma Insulin level 
The effect of the different doses of Ethanolic extract of Mallotus Philippensis 
Muell Arg on in plasma insulin level. 
Table no 13: Results of the effect of EEMP on Plasma insulin level 
Treatment and Dose  Insulin levels 
(μIU/ml) 
Control 0.5% 
CMC (1ml/kg; p.o) 
7.74 ± 0.41 
STZ  
(60mg/kg; b.wt; i.p) 
 
3.50 ± 0.73* 
STZ + Plant extract LD 
(200mg/kg, b.wt; p.o)  
 
5.01± 0.36** 
STZ+ Plant extract HD 
(400mg/kg, b.wt; p.o) 
6.75±0.98** 
STZ+ Glibinclamide  
(600 µg/kg, b.wt; p.o) 
 
7.58 ± 0.72** 
 
The values were expressed as Mean ± S.E.M. (n=6 animals in each group).  
*= when compared to the control group. 
** = when compared to the STZ treated group. 
Data was analysed by one-way ANOVA followed by Tukey’s multiple comparison test. 
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Fig. No-14: Diagrammatic representation of the results of the effects of EEMP on 
Plasma insulin level 
RESULTS 
The plasma insulin levels were measured and showed in Table no-13 and Fig. 
no-14. 
The diabetic control (Group 2) showed significant decrease in the plasma insulin 
levels when compared to the normal control (Group 1).  
Standard (Group 5) showed significant statistically increases in liver the plasma 
insulin levels when compared to diabetic control (Group 2). 
 EESO 200 mg/kg treated (Group 3) showed significant statistically increase in 
the plasma insulin levels when compared to the diabetic (Group 2).  
EESO 400mg/kg treated (Group 4) showed significant statistically increase in the 
plasma insulin levels when compared to the diabetic (Group 2). 
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7.9  HISTOPATHOLOGICAL STUDIES 
 
 
 
 
 
 
 
 
Group I normal control: showed the normal architecture of pancreas 
 
 
 
 
 
 
Group II STZ induced diabetes: Displayed extensive reduction in the number of islets, 
with a reduced number of betacells. Further atrophic islets cells where visualized. 
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 Group III STZ + M.philippensis (200 mg/kg): Showed the moderate restoration of 
pancreatic histology with a slight elevation of islets and beta cells . 
 
 
 
 
 
 
Group IV STZ + M. Philippensis (400 mg/kg): Effective restoration of 
pancreatic architecture with an increase in the population of islets and beta cells. 
 
 
 
 
 
 
Group V Standard Glibenclamide (600 µg/kg): Restored the normal architecture of 
pancreas with an increase in the number islets and beta cells 
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8. DISCUSSION 
Diabetes mellitus, a chronic metabolic disease characterized by a deficiency in 
the pancreas insulin production and/or by peripheral insulin resistance. 
The management of diabetes without any side effects is still a challenge to the 
medical system. Herbal drugs are prescribed widely because of their effectiveness, 
fewer side effects and relatively low cost. Wide array of plant derived active principles 
have demonstrated anti-diabetic activity. 
  The adverse effects of hypoglycaemic drugs and insulin and the excessive cost 
of these medications can be mentioned as some disadvantages regarding the diabetes 
treatment, which  stimulate the search for new therapeutic agents that present safety, 
effectiveness and low cost. Nowadays there is growing trend towards using herbal 
preparations and/or derivatives in traditional and complementary medicines to treat 
symptoms.122 In this way, it has been cresent the interest of current 
ethnopharmacological research to investigate the plants species with antihyperglycemic 
effect, focusing in the evaluation of the efficacy and safety of plant preparations for 
diabetic treatment. 
 The fundamental mechanism underlying hyperglycemia in diabetes involves over 
production (excessive glycogenolysis and gluconeogenesis) and decreased utilization of 
glucose by the tissues. The metabolism of glucose, proteins and lipids is abnormal in 
diabetes due to insulin secretion defect, leading to various metabolic disorders. Herbal 
drugs may act on blood glucose through different mechanism, some of them may have 
insulin like substances. Stimulation of beta cells to produce more insulin and others may 
increase cells in the pancreas by activating regeneration of pancreatic cell 
 The Mallotus Phililppensis Muell.Arg. Fruit had been claimed for its anti-diabetic 
activity and there is no degree of research work which has not been done but, claiming 
Mallotus philippensis Fruits have therapeutic use on blood glucose levels.90 Hence, 
project on Mallotus Phililppensis Muell. Arg. Fruit was carried out to provide scientific 
validation on anti-diabetic activity.   
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 The preliminary phytochemical analysis of EEMP revealed the presence of 
carbohydrates, flavanoids, terpenoids, glycosides, proteins, tannins, steroids and 
phenols. Mainly flavanoids which may be responsible for its anti-diabetic properties.113  
  Acute toxicity studies revealed the non-toxic nature of the EEMP There was no 
lethality or any toxic reactions found with high dose (2000 mg/kg body weight) till the 
end of the study. According to the OECD 423 guidelines (Acute Oral Toxicity: Acute 
Toxic Classic Method), an LD50 dose of 2000 mg/kg and above was considered as 
unclassified so the EEMP was found to be safe.  
Rats were rendered diabetic by a single intraperitoneal injection of freshly 
prepared streptazotocin (STZ-45mg/kg body weight) in 0.1M citrate buffer (pH 4.5) in a 
volume of 1ml/kg body weight.113 The diabetic group showed marked increase of 
glucose level as compared to the normal group. The oral administration of EEMP 
reversed the blood glucose level in which the action was through potentiation of 
pancreatic secretion of insulin from islets beta cells or due to enhanced transport of 
blood glucose to the peripheral tissue. There was a significant decrease in blood 
glucose level in the extract treated groups. 
Glycosylated haemoglobin concentrations are helpful and solid tool for the 
appraisal of glycemic control in diabetics as suggested by the international diabetes 
federation.123 Treatment groups (EEMP test low dose, EEMP test high dose and 
Glibenclamide) of diabetic rats unquestionably decrease the level of glycosylated 
haemoglobin. A noteworthy decrease of glycosylated haemoglobin showed the ability of 
the extract in the control of diabetes.124  
Hypercholesteremia are primary factor involved in the development of 
atherosclerosis and coronary heart diseases which are the secondary complications of 
diabetes.125 EEMP significantly reduced total cholesterol in STZ-diabetic rats. Thus, it is 
reasonable to conclude that EEMP, could modulate blood lipid abnormalities. 
The injection of STZ induces a hepatocellular damage, which is indicated by significant 
increase in AST and ALT in diabetic group as compare to control group. Furthermore 
STZ induces hepatocellular damage, which results in leakage of AST and ALT from liver 
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systole to the blood stream and/or may change the permeability of liver cell 
membrane.126 in the present study, EEMP significantly decreased AST and ALT 
enzyme activities in diabetic rats. The improvements in the levels of the enzyme are a 
consequence of an improvement in the carbohydrate, fat and protein metabolism. The 
restoration of AST and ALT after treatment also indicates a revival of insulin 
secretion.127The results from present study indicates that EEMP may reduce the level of 
serum cholesterol, SGOT and SGPT. It confirms that functions are on the protection of 
vital tissues Pancreas, thereby reducing the causation of diabetis in experimental 
animals.  
Lipid peroxidation eventually leads to extensive membrane damage and 
disfunction.128 Decreased lipid peroxidation and improved antioxidant status may be one 
of the mechanism by which drug treatment could contribute to the prevention of diabetic 
complications.129 In our study, EEMP significantly attenuated the increased lipid 
peroxidation which could be due to the antioxidant effect of flavanoids, detected in the 
preliminary phytochemical screening of the extract.  
Oxidative stress is a condition of reduction in antioxidative enzymes like SOD, 
CAT, GPx.130  
Superoxide dismutase (SOD), is an important defence enzyme which catalyses the 
dismutation of superoxide radicals, which scavenges the superoxide ions by catalyzing 
its dismutation. 
Catalase (CAT), a heme enzyme which removes hydrogen peroxide.131 The decreased 
activities of CAT and SOD thereby result in the increased production of hydrogen 
peroxide and oxygen by auto oxidation of glucose and non-enzymatic glycation,132 
which is known to occur during diabetis. 
Glutathione peroxidise (GPx) is an antioxidant enzyme, catalyses the scavenging and 
inactivation of hydrogen and lipid peroxidise.133 
The results showed that hepatic activity of catalase, superoxide dismutase and 
glutathione peroxidase decreased significantly in STZ induced diabetic group (Group II). 
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The normal control group maintained optimal value for activity of antioxidants. EEMP 
treatment in diabetic rats significantly increased the antioxidant enzyme activities and 
reversed them to their normal values. The same phenomenon was seen in the results of 
glibenclamide treated groups.  
An array of non-enzymatic antioxidant like GSH, Vitamin C and Vitamin E are 
involved in scavenging free radicals in vivo. 
Reduced glutathione (GSH), a tripeptide present in the all cells, is an important 
antioxidant.134 It is essential to maintain structural and functional integrity of cells. 
Hyperglycemia can increase oxidative stress and change the redox potential of 
glutathione.135 Decreased levels of GSH in liver of diabetic rats may increase their 
susceptibility to oxidative injury. 
Vitamin C is an excellent hydrophilic, dietary antioxidant and it readily scavenges ROS 
and peroxyl radicals.136 it also acts as co-antioxidant by generating Vitamin A, E and 
GSH from radicals. A decrease in the level of Vitamin C was observed in liver of 
diabetic rats. Such a fall in level of Vitamin C could be due to the increased utilization of 
Vitamin C in the deactivation of increased level of ROS or due to decrease in GSH 
level, since GSH is required in recycling of Vitamin C.137Another possibility is that 
hyperglycemia inhibits ascorbic acid and its cellular transport. 
Vitamin E is an antioxidant, a substance that helps prevent damage to the body’s 
cells.138 Streptozotocin induced diabetic rats were found to have decreased GSH, 
Vitamin C and Vitamin E levels in liver as compared to control rats. Treatment with 
EEMP and the standard drug, glibenclamide produced significant increase in the levels 
of these non-enzymatic antioxidants. 
The serum insulin level decreased in diabetic rats, whereas EEMP extract, 
brought about a marked increase in serum insulin in streptozotocin-induced diabetic 
rats. This increase may be a consequence of the stimulation of insulin synthesis and 
secretion.139 
 The histopathological investigation along with the biochemical evaluation 
suggests the possibility of the islets regeneration and recovery of normal carbohydrate 
metabolism in treated group EEMP. The regenerative effect of the pancreatic cells by 
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Mallotus philippensis via exocrine cells of pancreas may enlighten the positive effects of 
these agents on the production of insulin. Reports on histopathological analysis of 
pancreas of the Mallotus philippensis alone treated rats showed results that were very 
similar as that of the control group. 
 Based on the above results, it was concluded that Mallotus Phililppensis 
Muell.Arg. exerted statistically significant anti-diabetic activity against STZ induced 
diabetic rats.  
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9. SUMMARY AND CONCLUSION 
 The present study was undertaken to scientifically elucidate the anti-diabetic 
activity of alcoholic fruit extract of Mallotus Phililppensis Muell.Arg. 
 The phytochemical investigation revealed the presence of carbohydrates, 
steroids, phenols, tannins, flavanoids, glycosides, and terpenes in the EEMP. 
 The STZ 45 mg/kg effectively induced diabetes, which was similar to diabetes in 
human. Therefore it is an effective and an ideal model for diabetes research. 
 The Blood glucose level and Glycosylated haemoglobin level significantly 
decreased with treatment of EEMP proves it having anti-diabetic activity. 
 Attenuating the increased serum parameters like total cholesterol, AST and ALT 
with treatment of EEMP showed its anti-diabetic activity. 
 Reduced level of lipid peroxidation in EEMP treated rats, showed EEMP has 
protective effect in oxidative stress induced diabetes. 
The enzymic antioxidant parameters such as SOD, CAT and GPx and  
Non-enzymic antioxidant parameters such as GSH, Vitamin C and Vitamin E are 
increased significantly with treatment of EEMP, which proved as it having antioxidant  
activity. 
The plasma insulin level significantly increased with treatment of EEMP, showed 
the EEMP in managing hyperglycemia and diabetic complications. 
Mallotus Phililppensis Muell.Arg.fruit extract also have favourable effects to 
inhibit the histopathological change of the pancreas in STZ induced diabetes. 
In summary, alcoholic fruit extract  of Mallotus Phililppensis Muell.Arg showed 
statistically significant anti-diabetic activity. 
 In conclusion, the alcoholic fruit extract of Mallotus Phililppensis Muell.Arg. 
showed and offered a promising therapeutic value in prevention of diabetes. These 
effects was mainly attributed to its antioxidant properties by significant quenching 
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impact of the extract on lipid peroxidation along with enhancement of enzymatic and 
non-enzymatic antioxidant defense systems in liver and pancreatic tissue. 
 Further studies will be needed in future to determine the exact phytoconstituents 
in the extract, which having anti-diabetic activity. 
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10. FUTURE PROSPECTIVES  
 
 Further study is required., 
1.  To isolate and separate the active phytochemicals present in the ethanolic extract of 
the Fruit of Mallotus Phililppensis Muell Arg.  
2. Formulation of the isolated lead molecule can be designed. 
3. Clinical trial of the formulated molecule in healthy human volunteers or diseased 
persons. 
4. The formulated lead molecule can be subjected to the clinical trials, patented and 
marketed for the treatment of diabetes. 
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